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ABSTRACT 
 
 
BACKGROUND  
 
Adequate blood circulation is necessary for tissue perfusion and oxygen supply. 
Derangements in perfusion due to circulatory failure may lead to end-organ failure 
without prompt and accurate restoration of circulation and perfusion, which is performed 
by targeting sufficient levels of preload, afterload, and cardiac contractility. Current 
international guidelines recommend early vigorous fluid resuscitation, restoration of 
mean arterial pressure (MAP) to ≥60-65 mmHg, when necessary by using vasopre ssor 
agents, and restoration of depressed cardiac contractility and output by inotrope 
treatment to improve survival and avoid end-organ failure. However, evidence for the 
beneficial impact of inotrope use in septic shock, hemodynamic targets for resuscitation 
in severe acute pancreatitis (SAP), or optimal blood pressure for prevention of septic 
acute kidney injury is rather limited. Furthermore, feasible means of assessing fluid 
responsiveness to prevent excessive fluid resuscitation are warranted. The objective of 
this study was to evaluate different hemodynamic variables in addition to vasopressor and 
inotrope treatment during the early phases of severe sepsis, septic shock, and SAP and 
their association with development of end-organ failure and outcome. We also sought to 
find relevant hemodynamic parameters for assessing fluid responsiveness during early 
resuscitation of septic shock. 
 
 
PATIENTS  
 
A total of 1022 patients, 440 with septic shock, 159 with SAP, and 423 with severe sepsis, 
were included in the study. All patients were treated in the ICUs of Helsinki University 
Hospital during 2005-2012, except for the 423 patients with severe sepsis, who were 
treated in 13 different Finnish ICUs during 2011-2012.  
 
 
MAIN RESULTS 
 
Of patients with septic shock, 44.3% received inotrope treatment during the first 24 hours 
in the ICU, the majority of these patients receiving dobutamine (90.3%). The mortality of 
inotrope receivers was significantly higher than that of non-receivers (42.5% vs. 23.9%).  
Patients who received inotropes were generally more severely ill and received higher 
doses of norepinephrine. The use of inotropes in these patients was independently 
associated with worse outcome, also after adjustment with propensity score. In patients 
with severe sepsis and SAP, the use of inotropes was less frequent, 16.0% and 16.4%, 
respectively. Vasopressors, most often norepinephrine, were administered to the majority 
of patients with severe sepsis, SAP, and septic shock. The highest dose of norepinephrine 
during the first day in ICU was associated with worse outcome. 
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Lower MAP, higher central venous pressure (CVP), and lower cardiac index (CI), but not 
higher heart rate (HR), were associated with 90-day mortality in patients with SAP.  
 
Decreases in MAP and systolic arterial pressure were the best predictors of fluid 
responsiveness in 20 mechanically ventilated patients with septic shock during a 
temporary elevation of positive end-expiratory pressure (PEEP) from 10 to 20 cm H2O. A 
decrease of less than 8% ruled out fluid responsiveness, with a negative predictive value 
of 100%. 
 
The time-adjusted MAP during the first 24 hours in the ICU of patients developing acute 
kidney injury (AKI) during the first five days in the ICU was significantly lower than that 
of patients not developing AKI (74.4 mmHg vs. 78.6 mmHg). The best cut-off value for 
time-adjusted MAP was 72.7 mmHg. Lower time-adjusted MAP or alternatively time-
adjusted MAP below 73 mmHg was independently associated with progression of AKI. 
 
 
CONCLUSIONS 
 
Inotropes are frequently used in patients with septic shock. In severe sepsis and SAP, 
inotrope use is less frequent. The vast majority of patients received vasopressor 
treatment. Norepinephrine was the vasopressor of choice in nearly all patients. Use of 
inotropes and the highest vasopressor dose during the first day in ICU were significantly 
associated with 90-day mortality.  
Although inotropes may have beneficial effects in patients with septic shock, by increasing 
cardiac output and perfusion, they might also have adverse effects that eventually lead to 
higher mortality.  Although vigorous fluid resuscitation is advocated in the early 
treatment of SAP to maintain sufficient tissue perfusion, our study showed that 
overzealous resuscitation might be harmful, reflected by the association of higher CVP 
with worse outcome. To avoid overhydration during fluid resuscitation of patients with 
septic shock, a lack of a decrease in MAP during elevation of PEEP from 10 to 20 cm H2O 
may be used as an accessory means of assessing fluid responsiveness. Lower time-
adjusted MAP in patients with severe sepsis is associated with progression of AKI.  Higher 
targets of MAP may be indicated for ensuring adequate perfusion of the kidney in this 
patient group.  
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ABBREVIATIONS 
 
 
 
AKI Acute kidney injury 
APACHE Acute Physiology and Chronic Health Evaluation 
ARDS Adult respiratory distress syndrome 
CI Cardiac index 
CO  Cardiac output 
CPR Cardiopulmonary resuscitation 
CVP Central venous pressure 
DIC Disseminated intravascular coagulation 
DO2  Oxygen supply 
HES Hydroxy ethyl starch 
HR Heart rate 
IABP  Intra-aortic balloon pump 
IAP  Intra-abdominal pressure 
ICD-10 International Classification of Diseases, tenth revision 
ICU  Intensive care unit 
IL Interleukin 
iNOS  Inducible nitric oxide synthetase 
KDIGO Kidney Disease: Improving Global Outcomes 
LV Left ventricle 
LVEDA Left ventricular end-diastolic area 
LVEF Left ventricular ejection fraction 
MAP Mean arterial pressure 
MDRD  Modification in Diet in Renal Disease (equation) 
MMDS  Microcirculatory and mitochondrial dysfunction syndrome 
MOD Multiple organ dysfunction  
MPAP Mean pulmonary artery pressure 
MRI Magnetic resonance imaging 
NIRS Near-infrared spectroscopy 
NO Nitric oxide 
O2  Oxygen 
OPS Orthogonal polarization spectral imaging 
PAC  Pulmonary artery catheter  
PAOP Pulmonary artery occlusion pressure 
PEEP Positive end-expiratory pressure 
PLR Passive leg raising 
PPV Pulse pressure variation 
RRT Renal replacement therapy 
SAE  Sepsis-associated encephalopathy 
SAP Severe acute pancreatitis 
∆SAP Change in systolic arterial pressure 
SAPS  Simplified Acute Physiology Score 
SCr Serum creatinine 
ScVO2  Central venous oxygen saturation 
SDF Sidestream dark field imaging 
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SOFA Sequential Organ Failure Assessment 
STEMI ST-elevation myocardial infarction 
SV Stroke volume 
SVO2 Mixed venous oxygen saturation 
SVV Stroke volume variation 
TEE Transesophageal echocardiography 
TM  Thrombomodulin 
TNF Tumor necrosis factor 
TTE Transthoracic echocardiography 
VO2 Oxygen supply 
VTIAo Aortic velocity time integral 
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1. INTRODUCTION 
 
 
Human hemodynamics has intrigued medical practitioners, philosophers, and scientists 
for over two thousand years. We have come a long way in our understanding of 
hemodynamics since the Galenic era, which dominated medical practice for over 1600 
years. Galen of Pergamon (129-200 AD), who gained fame as a surgeon to the 
gladiators, was convinced that hemorrhage was one of the conditions that benefited 
from bloodletting. He was also convinced that blood flowed outwards in both veins and 
arteries from the liver, where it was constantly formed. The erroneous notions were not 
corrected until 1543, when Andreas Vesalius published “De Humanis Corporis Fabrica”.1 
A lesser known fact is that Leonardo da Vinci (1452-1519) spent his last years of life 
studying the anatomy of the cardiovascular system, depicting the vessels and the 
function of cardiac valves with surprising accuracy.2 	  	  
	  
Figure 1. Leonardo da Vinci’s study of an ox’s heart c. 1511-1513 
Royal Collection Trust / © Her Majesty Queen Elizabeth II 2013 
 	  
The English physiologist William Harvey (1578-1657) made two seminal discoveries 
without which modern understanding of hemodynamics and shock would not be 
possible. Firstly, he noted that blood circulated from the heart in the arteries and to the 
heart in the veins. Secondly, based on his calculations of cardiac output, he also 
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determined that blood could not be formed in the liver, but was in constant circulation. 
The term “shock” was first used in a translation of Henri-Francois Le Dran’s article 
describing gun shot wounds in the 1740s.  The word was, however, rarely used in this 
context for the following century. Moreover, it was exclusively used for gunshot wounds 
until the American Civil War, when Dr. Samuel Gross published a manual for military 
surgeons in 1861. He realized that shock was a physiologic response to many forms of 
injury and focused on the neurologic findings of this physiologic state. By the end of 
World War I, “wound shock” or “traumatic shock” was thought to be a two-stage 
phenomenon. Primary shock was considered a neurologic entity and secondary shock 
was presumably caused by toxins that led to hypotension by pooling of the blood in the 
capillaries. 1 
 
Alfred Blalock first described the importance of blood volume in the development of 
shock in the 1920s. Blalock proposed a classification of shock based on the four principal 
underlying mechanisms; his classification is highly similar to the one still in use today. 
Blalock produced 44 scientific articles during 1927-1942, shedding more light on this 
enigmatic phenomenon than anyone before him. 1 
 
During the Crimean war in the 1850s Florence Nightingale created separate care 
areas for the most severely injured soldiers. This has been cited as the beginning of 
intensive care. Modern intensive care began evolving during the 1950s, triggered by the 
Danish poliomyelitis epidemy and the need for respiratory support. In the mid 20th 
century, dialysis machines were already used for renal failure, and hemodynamic and 
cardiac care developed as alternating current defibrillators and patient monitors were 
introduced to the market. The founders of the two first American Intensive Care Units, 
M.H. Weil and P. Safar together with W.C. Shoemaker, founder of the first trauma 
center in Chicago, were pioneers in the field of critical care medicine throughout the 20th 
century. 3,4 In addition to their vast clinical work, they produced more than 1300 
scientific articles establishing much of the foundations of intensive care as we know it 
today. 
 
In the non-cardiac ICU, severe sepsis and septic shock are among the leading causes 
of death.5 Sepsis, severe sepsis, and septic shock have for many years been on the list of 
the 10 leading causes of death in the United States. 6 Published in-hospital mortality rates 
of severe sepsis and septic shock have varied from 25% to 70%. 7 In a recent large study of 
nationwide inpatient data, the incidence of severe sepsis increased from 200 to 300/100 
000 in the total American population during 2003-2007.8 These results closely agree with 
those of earlier studies. 5,9  
 
Severe sepsis accounts for about 6-15% of all ICU admissions, a proportion showing 
remarkable consistency across studies. 10-14 In the FINNSEPSIS study, severe sepsis 
accounted for 11% of Finnish ICU admissions, and 28% of these patients died in hospital. 
10 The proportion varies slightly according to local or national ICU resources and the 
proportion of beds reserved for the most critically ill. 12 Although mortality rates seem to 
decrease, along with ICU lengths of stay and mean cost per case, this effect is attenuated 
by the rising incidence of severe sepsis, resulting in a continuous increase in treatment 
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costs. 8 There is also evidence that the proportion of patients with severe sepsis and 
multiple organ failures is increasing, while the proportion of patients with single organ 
failure is declining. 8 
 
Severe sepsis is defined as a systemic inflammatory response to infection complicated 
by organ dysfunction, hypoperfusion, or sepsis-induced hypotension, while septic shock is 
characterized by evidence of hypotension or hypoperfusion, which is not resolved by 
adequate fluid resuscitation. 15 A more profound hemodynamic compromise has been 
associated with more severe organ dysfunction and worse outcome, and early 
hemodynamic optimization has become the mainstay of treatment of these conditions. 
12,16  
 
In severe acute pancreatitis, the microcirculation of the pancreas is deranged 17 and 
the decrease in systemic vascular resistance along with the cytokine and inflammatory 
mediator profiles are comparable to changes occurring in severe sepsis and septic shock. 
18 Although aggressive and vigorous fluid therapy is currently advocated for the treatment 
of patients with severe acute pancreatitis,17 there is remarkable lack of knowledge 
regarding its administration and optimal hemodynamic targets. 19,20 Insufficient data also 
exist on the association of early hemodynamic function with later progress and outcome 
of the disease.  
 
The incidence of acute pancreatitis has also been shown to increase.21 In the United 
States, acute pancreatitis accounts for about 200 000 hospital admissions each year. 17 In 
the Finnish population, acute pancreatitis leads to 70 hospitalizations /100 000 
population, indicating an annual total of nearly 4000 hospital admissions.21 Mortality due 
to acute pancreatitis has decreased only slightly over the last decades. 17 For severe acute 
pancreatitis, which develops in one-fifth of all cases, mortality rates of 20-30% have been 
reported. 22-24 
 
Although inotrope treatment is included in current sepsis treatment guidelines,16 
insufficient evidence of a beneficial effect in terms of outcome exists.  These 
recommendations are mainly based on expert opinion and on incorporation of inotropes 
into treatment bundles that have been shown to improve survival.16,25 However, growing 
evidence has emerged that catecholamine inotropes are associated with increased 
mortality in patients with heart failure. 26-28 Moreover, no benefit was seen in terms of 
improved survival when inotropes were administered in order to increase oxygen delivery 
to a supranormal level in critically ill patients. 29 Evidence indicates several adverse effects 
of inotropes, including increased myocardial oxygen consumption and an elevated risk of 
both arrhythmias and myocardial ischemia. 30-32 Inotropes may also cause metabolic 
disturbances and increased bacterial growth.33 Some evidence also suggests that 
dobutamine may have pro-inflammatory effects. 34 
 
There is little debate today of whether fluid resuscitation is an essential part of early 
hemodynamic optimization of patients with septic shock.  35 At the same time, increasing 
evidence is emerging in support of an association between higher fluid load and worse 
outcome. There is broad agreement that invasive (static) filling pressures, such as central 
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venous pressure and pulmonary occlusion pressure, are poor markers of preload and ill 
suited for prediction of fluid responsiveness in these patients. 36,37 In recent years, the 
focus has been on the dynamic indices of preload and functional hemodynamic 
monitoring. By utilizing cardiorespiratory interactions and their impact on venous return 
and cardiac output, fluid responsiveness may be predicted at bedside.38 Though superior 
to static measurements, there are several limitations to the clinical use of dynamic 
indices, of which the lack of suitable monitoring devices is merely one.  Easy and feasible 
means of assessing fluid responsiveness for everyday use by ICU clinicians are required. 
 
Acute kidney injury (AKI) occurs frequently in patients with severe sepsis, septic 
shock, and severe acute pancreatitis. 39,40 In severe sepsis, AKI develops in approximately 
half of the patients. Severe sepsis and septic shock are the primary etiological factors for 
AKI in nearly half of all critically ill patients. 40 Septic patients with AKI have worse 
outcome than those with preserved renal function, which is also true for patients with 
severe acute pancreatitis. 40,41 Septic AKI is not only the consequence of alterations in 
kidney perfusion due to hemodynamic failure. However, hemodynamics plays a role in 
the development and progression of this condition. Autoregulation is altered during 
severe sepsis and septic shock, rendering kidney perfusion vulnerable to hemodynamic 
changes and more dependent on blood pressure levels and cardiac output. Some studies 
have reported that maintaining higher levels of blood pressure in patients with septic 
shock than those currently recommended (≥ 65 mmHg) would be beneficial for 
preservation of kidney function.42,43 Evidence also suggests that administration of 
norepinephrine to patients in septic shock improves kidney perfusion and glomerular 
filtration rate. 44 However, raising blood pressure using catecholamine vasopressors is 
also associated with potential harm.  45 
 
Despite numerous advances in the field of hemodynamic treatment of severe sepsis, 
septic shock, and severe acute pancreatitis, much remains to be done. This study was 
prompted by the lack of evidence of beneficial effects of inotropes in septic shock and 
insufficient knowledge of how to optimally resuscitate a patient with severe acute 
pancreatitis. Moreover, there is a demand for feasible ways of assessing fluid 
responsiveness to avoid excess fluid with deleterious effects. Lastly, optimization of 
kidney perfusion and blood flow is still one of the only means to prevent the progression 
of septic AKI. While studies of the underlying pathophysiology of septic AKI are 
underway, clinicians are left with few specific means of improving the outcome of these 
patients. Knowledge of the association of hemodynamic variables and vasoactive support 
with progression of AKI may, by way of further randomized studies, lead to better 
outcomes of these patients in the future. 
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2. REVIEW OF THE LITERATURE 
 
2.1 DEFINITION OF HEMODYNAMICS 
 
Circulation of blood through the cardiovascular system is essential for the transport of 
oxygen and metabolites to the cells of all tissues of the body. 
The term hemodynamics is used to describe the forces that the heart must generate to 
circulate blood through the cardiovascular system. This system is made up of the heart 
and the network of arteries, veins, and capillaries that transports the blood to, through, 
and from the tissues.  
 
Adequate hemodynamics can also be defined in terms of bioenergetics. Adequate 
hemodynamics prevails when the transport of oxygen and metabolites to the cells and the 
subsequent clearing of waste products meet the tissues’ needs.  46 
 
 
 
2.1.1 DEFINITION OF HEMODYNAMIC INSTABILITY OR FAILURE 
 
In 1862, the American academic trauma surgeon Samuel D. Gross described 
hemodynamic failure as the ”rude unhinging of the machinery of life”.  47 ”Machinery of 
life” eloquently describes cell metabolism, oxygen supply, and consumption as we 
understand it today.   
 
The term hemodynamic instability may be used to describe the clinical situation in 
which perfusion failure manifests as features of circulatory shock or advanced cardiac 
failure, or it may be used to describe less severe conditions where one or more 
measurements are not in the normal range, but are not clearly pathological. In the 
literature, other synonyms for hemodynamic instability, such as hemodynamic or 
circulatory failure, or simply shock, are also frequently used to describe the same 
phenomenon. Shock is defined as hemodynamic instability leading to hypoperfusion and 
a decrease in oxygen supply to the tissues. 48 
 
The physical findings of hemodynamic failure include hypotension, abnormal heart 
rate, changes in mentation or consciousness, cold extremities, skin mottling, and cyanotic 
periphery, in addition to oliguria or anuria. 46,49,50 These clinical manifestations reflect 
perfusion failure, in other words, the imbalance between the needs of the tissues and the 
supply of oxygen and energy that they receive. 46 Hemodynamic failure is usually a 
systemic complication of an underlying disease.  In everyday clinical practice, this 
emphasizes the importance of the clinical examination and careful history taking. 
Treatment of hemodynamic failure is usually not fully successful without knowledge of 
the underlying condition.  46,49 
 
In clinical practice, physicians define hemodynamic failure by a combination of 
clinical findings, as mentioned above. The common denominator for these signs is the 
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deterioration of systemic and microvascular blood flow, but the underlying hemodynamic 
mechanism differs according to which part of the circulatory system is most severely 
afflicted. These differing mechanisms create the basis for the classification of types of 
hemodynamic failure.  46,49 
 
During recent years the focus of hemodynamic failure has turned to the insufficiency 
and dysfunction of the microcirculation and the subsequent or concomitant malfunction 
of cells and organelles responsible for energy production. The microcirculation is now 
considered the battlefield of shock pathophysiology. It has become apparent that an 
improvement of macrocirculatory parameters alone, without restoring the 
microcirculation, is insufficient in the battle against circulatory shock and the end-organ 
damage and high mortality that it causes in critically ill patients.  51 
 
 
 
2.1.2 CARDIOVASCULAR SYSTEM 
 
In a simplified model, the hemodynamic system constitutes the pump, represented by the 
heart, the plumbing, represented by the vasculature, and the fluid being pumped, 
represented by the blood in the vessels.   
 
The human heart works as a double pump surrounded by a common lining, the 
pericardium. It comprises four separate chambers, namely the left atrium and ventricle 
and the right atrium and ventricle. Systole stands for the phase of contraction of the 
ventricles, while diastole stands for the phase of filling of the ventricles, during which the 
atria contract to enhance ventricular filling.52 The pericardium renders the different 
chambers of the heart dependent on each other; the filling of the right ventricle impedes 
the filling of the left ventricle and vice versa.  Moreover, the left ventricle receives the 
blood that the right ventricle has ejected a few heartbeats earlier, defined as series 
interdependence of the ventricles (parallel and series interventricular 
interdependence).53-55 
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Figure 2. Structure and blood flow of the heart. Modified from Hall JE, Guyton AC. 
Guyton and Hall Textbook of Medical Physiology, 2011, with permission by Elsevier. 52 	  	  
	  
Figure 3. Distribution of blood in different parts of the circulatory system. Modified from 
Hall JE, Guyton AC. Guyton and Hall Textbook of Medical Physiology, 2011, with 
permission by Elsevier. 52 
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The systemic and pulmonary circulation can be described in a simplified manner as 
follows: The left atrium receives oxygenated blood from the lungs through the pulmonary 
veins. The blood then enters the left ventricle, from where it is ejected into the aorta, and 
from there it is further directed into the arteries of the systemic circulation. The arteries 
then gradually branch and narrow into smaller arteries, or arterioles, as they further 
branch into the capillary system. The capillaries, which are the smallest vessels in the 
body, are responsible for the microcirculation and the perfusion of the tissues. After 
perfusion of the tissues, the capillaries join to form venules, which further join into larger 
veins. Finally, the veins join the inferior or superior vena cava, which transports the 
deoxygenated blood into the right atrium. From the right atrium, the blood is transported 
into the right ventricle, from where it is ejected into the pulmonary arteries of the lungs. 
In the lungs, the blood is re-oxygenated during its passage through the alveolar vessels 
and then returned to the left atrium. 52 
 
 
2.1.3 MACROVASCULAR HEMODYNAMICS – PHYSIOLOGY OF VENOUS 
RETURN AND CARDIAC FUNCTION 
 
In terms of physiology, the mechanism of the left ventricle can be depicted by the cardiac 
function curve, which describes the amount of blood ejected by the left ventricle into the 
systemic circulation (cardiac output) relative to the amount of blood it has received from 
the venous flow in terms of right atrial pressure (preload).  52,55 It is loosely related to the 
Frank-Starling law of the heart, which states that: ”in normal hearts, diastolic volume is 
the principal force that governs the strength of ventricular contraction”. Cardiac output 
(CO) is the term used to describe the amount of blood that the heart pumps into the 
vasculature during one minute. The slope of the cardiac function curve may vary 
according to the contractile function of the left ventricle. The cardiac function curve of a 
heart with depressed contractility is less steep than that of the normal heart. For every 
increase in preload, there is a lesser increase in cardiac output than for the normal heart.   
52,53,55 
 
Likewise, the return of the deoxygenated blood to the right atrium may be described 
by the venous return curve. The venous return curve depicts the flow of venous return in 
relation to the pressure in the right atrium. The slope of the venous return curve is also 
affected by the resistance to venous return.  Over time the cardiac output must equal the 
venous return and vice versa, as the heart can only eject what it receives. 53,55-57 The 
driving force of the venous return is the mean systemic filling pressure, which is the 
pressure measured in the vessels of the cardiovascular system when pumping of the blood 
by the heart has ceased and there is no flow through the vessels. The mean systemic filling 
pressure cannot therefore normally be measured at bedside. The venous system has a 
high compliance and capacitance (distensibility) compared with the arterial system.  
Approximately 70% of the blood volume is located in the venous system. Most of the 
blood forms the unstressed volume, which is defined as the blood volume that fills the 
veins, without causing tension to the vessel walls.  The stressed volume is the part of the 
blood volume that resides in the veins, causing wall tension and thus building up the 
mean circulatory filling pressure driving the venous return towards the heart, as shown in 
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Figure 4 a. 53,55 The combination of the cardiac function curve and the venous return curve 
can be used to describe the physiology of the cardiovascular system. The cross-section of 
the two curves indicates the operating point for the cardiovascular system  (Figure 4 b). 55 	  	  
	  	  
Figure 4.  Venous return function and cardiac function. Q: flow, Rv: resistance to venous 
return, Pra: right atrial pressure, MCFP:  mean circulatory filling pressure, VR= venous 
return. Permission granted by Wolters Kluwer Health. S.Magder, Fluid status and fluid 
responsiveness, Current Opinion in Critical Care, 16:4, p. 290, 2010. 60 	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2.1.4.  MICROVASCULAR FUNCTION AND TISSUE PERFUSION 
 
The task of the microcirculation is to perform the final steps of the transport of oxygen 
from the vessels to the cells. The microcirculation is strategically placed at the interface 
between the circulatory system (supplier) and the parenchymal cells (consumers). The 
microvessels, or the capillaries, are the narrowest and most distal of the vessels in the 
cardiovascular system. Each cell of the parenchymal tissues is situated in close vicinity to 
at least one capillary, so that passive diffusion can ensure an efficient supply of oxygen to 
the cell. Due to high permeability of arteriolar walls to oxygen, arterioles also represent a 
major source of oxygen to tissues of low blood flow.  58 	  
Ultimately, the oxygen is transported into the cells, and further into the mitochondria, 
located in the nuclei of the cells, where it is consumed in energy production processes. 
Integrity of this chain of events is essential for normal function of the tissues. When 
energy requests of the cells are not met, energy failure follows. Cells may then attempt to 
adapt to the situation, but if adaptation fails, apoptosis or necrosis of the cells will follow, 
resulting in end-organ damage.  46,59 
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2.2 CLASSIFICATION OF HEMODYNAMIC FAILURE 
 
The definition of hemodynamic failure is based on the mechanism or the specific part of 
the cardiovascular system that is most severely affected. The basis for the classification of 
types of hemodynamic failure, or more commonly, types of shock, was first proposed by 
Weil and Shubin in 1968 and further developed and abbreviated by Weil and Shubin in 
1971.  46,61,62 The four categorical states of shock are 1) hypovolemic shock, 2) cardiogenic 
shock, 3) obstructive shock, and 4) distributive shock. Clinically, hemodynamic failure 
may possess features of more than one of the four main types. 49 Patients with distributive 
shock caused by sepsis may also have depressed myocardial contractility, which is 
characteristic of cardiogenic shock, or they may have intravascular fluid loss, which is 
associated with hypovolemic shock.  49,63 
 
For better understanding of the classification of shock types, the mechanisms 
responsible for the instability of the cardiovascular system can be divided into eight main 
mechanisms or sites of dysfunction as proposed by Weil: 49,62,63 
 
 
1) Preload or venous return  
2) Cardiac function, contractility, and rhythm 
3) Afterload or arteriolar resistance to flow 
4) Capillary exchange, substrate exchange, and fluid shifts 
5) Venular resistance control of capillary hydrostatic pressure 
6) Arteriovenous shunt 
7) Venous capacitance  
8) Mainstream patency  
 
 	  
2.2.1. HYPOVOLEMIC SHOCK 
 
Hypovolemic shock is probably the most frequent type of hemodynamic failure caused by 
a decrease in venous return.  64 Hypovolemic shock is caused by a critical reduction of the 
intravascular volume by blood loss (hemorrhage) or other fluid losses such as losses from 
the gastrointestinal tract due to diarrhea or vomiting, or inflammatory fluid losses into 
bodily cavities due to trauma or infection. It may also be caused by surface fluid losses 
due to burns, by failure of fluid intake, or by endocrinological disturbances such as 
diabetes insipidus.  49,65 
 
Hypovolemia causes shock by decreasing primarily the stressed, but eventually also the 
unstressed volume, leading to a decrease in venous return. The decrease in venous return 
subsequently decreases cardiac output, as a consequence of the decrease in cardiac 
preload.  57 
	   23	  
Fluid losses activate the sympathetic system, which increases the release of 
catecholamines. This may temporarily compensate for lesser volume losses by causing 
venoconstriction and thus increasing the stressed blood volume and venous return. 
However, when losses exceed 40% of the blood volume, most patients will develop 
hypotension. When the compensatory threshold is reached, the decrease in venous return 
and cardiac output will lead to manifestations of frank shock. 57,64 	  
 
2.2.2. CARDIOGENIC SHOCK 
 
In cardiogenic shock, cardiac failure causes end-organ hypoperfusion. 66 Cardiogenic 
shock may be caused by a variety of cardiac mechanisms that lead to the fairly rapid 
deterioration of the pumping function of the heart, ultimately resulting in a decrease in 
cardiac output and shock.  64,65 Microcirculatory, neurohumoral, and cytokine factors are 
also involved in the development of this entity of shock.  66 
 
The most common cause of cardiogenic shock is myocardial ischemia or infarction, 
usually within 24 hours of the primary insult.  67 The loss of approximately 40% or more 
of the ventricular muscle mass due to infarction frequently leads to cardiogenic shock.65,68 
Cardiogenic shock may also be caused by a variety of mechanical complications of 
myocardial infarction such as rupture of the ventricular free wall, septum, or papillary 
muscles. 66 Other causes of myocardial dysfunction and cardiogenic shock include acute 
myopericarditis, tako-tsubo cardiomyopathy, or hypertrophic cardiomyopathy.  66 
 
Valvular dysfunction may cause cardiogenic shock either by impeding the ejection of 
the ventricle (stenosis) or by regurgitation due to valvular insufficiency.  Most frequently, 
the cause of valvular cardiogenic shock is acute mitral valve regurgitation due to rupture 
or malfunction of the chordae tendinae or papillary muscles as a complication of 
myocardial infarction.  64-66 
 
Tachyarrhythmias or bradyarrythmias may also cause cardiogenic shock. These 
dysrhythmias, of which tachyarrythmias of ventricular origin are the most ominous, may 
often be consequences of underlying systemic or cardiac causes. A thorough clinical 
examination is essential for detecting possible underlying causes such as myocardial 
ischemia and metabolic disturbances. 69 Anti-arrythmogenic therapy often fails if the 
underlying cause is left untreated.  64 
 
Finally, cardiogenic shock may also be due to deterioration of left ventricular diastolic 
function. Diastolic dysfunction is more difficult to assess than systolic function. 
Derangements in relaxation and compliance likely contribute to many if not all cases of 
cardiogenic shock. Diastolic dysfunction may lead to shock through failure to receive and 
consequently eject the required cardiac output. 66 
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2.2.3 OBSTRUCTIVE SHOCK 
 
Obstructive shock is characterized by a mainstream obstruction to flow, which leads to a 
reduction of cardiac output. 49,63,64 Cardiac tamponade, pneumothorax, and massive 
pulmonary embolism cause obstruction to venous return by increasing right atrial 
pressure or right ventricular afterload. 57,70 Obstructive shock may also be caused by a 
thrombus of a artificial heart valve or dissection of the aorta by obstructing outflow from 
the (left) ventricle. In the early phases, obstructive shock may be difficult to distinguish 
from cardiogenic shock. Some of the subtypes of obstructive shock may also possess 
features of obstructive as well as cardiogenic shock (cardiac tamponade).  64 
 
 
 
2.2.4 DISTRIBUTIVE SHOCK 
 
Distributive shock can be defined as any physiological condition that results in 
maldistribution of blood flow (arterial, capillary, and venous) in the absence of primary 
cardiac dysfunction.  64 Distributive shock accounts for an array of different conditions, all 
of which lead to a common hemodynamic picture. The classical hemodynamic pattern in 
distributive shock is that of high cardiac output and systemic hypotension.  64,65 Although 
septic shock is the most common type of distributive shock, a similar hemodynamic 
profile may be caused by non-infectious conditions, such as anaphylaxis, spinal cord 
injury, drug-induced expansion of the venous capacitance beds, or decreased arteriolar 
resistance, and by severe forms of liver dysfunction.  46,65 It may also be caused by rare 
systemic diseases such as capillary leak syndrome. 71 Contrary to the three other forms of 
shock, distributive shock is usually, especially in the early stages, characterized by normal 
or increased cardiac output.  65 	  
Neurogenic shock results from upper thoracic spinal cord injury and subsequent loss 
of sympathetic vascular tone. It manifests as hypotension and bradycardia, with warm dry 
skin. Patients with neurogenic shock show symptoms of hypovolemia as a result of 
vasodilation, while actually being euvolemic.  65 
 
Anaphylactic shock is a form of distributive shock in which vasodilation, hypotension, 
and redistribution of blood flow is caused mainly by the liberation of histamine in 
response to medication, insect bites and stings, blood products, or food allergies.  64 As a 
reaction to allergens, through mechanisms of antigen-antibody binding, mast cells 
liberate cytotoxic substances, such as histamine and leukotrienes, which affect the heart, 
circulation, and peripheral tissues. The permeability of the endothelium is markedly 
increased, leading to extravasation of fluid and proteins to the extravascular space. In rare 
cases, anaphylactic reactions also lead to depression of cardiac contractility.  64,65,72 
 
Septic shock is defined as hypotension induced by sepsis, which persists despite 
adequate fluid resuscitation. 73 It is one of the major challenges for physicians working in 
the ICU because of its complexity, high incidence, and high mortality.  Though great 
advances have been made during recent years in elucidating the complex nature and 
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pathophysiology of septic shock, many questions remain unanswered.  74 In septic shock, 
inflammatory mediators, including cytokines, cause vasodilation, but also concomitant 
vasoconstriction. Some mediators cause myocardial depression, but despite this effect, 
cardiac output is usually increased. Activated leukocytes and platelets cause obstruction 
of the microvasculature, which leads to loss of autoregulatory functions of peripheral 
tissues and a mismatch between oxygen supply and demand. 63 It has been stated that the 
main pathophysiologic feature of septic shock is the maldistribution of blood flow and 
shunting of oxygen supply to the tissues.  64,75 
 	  	  
 
2.3 PATHOPHYSIOLOGY OF CIRCULATORY SHOCK 
 
Derangements in one or many of the components of the circulatory system may 
ultimately lead to the development of shock. The division of shock types into the four 
main types is performed based on the principal underlying mechanisms for development 
of shock.  49,62,76,77 
 
The intravascular volume, the heart, and the resistance circuit constitute three 
important mechanisms in which alterations may lead to the development of circulatory 
shock. The intravascular circulating volume is essential for regulation of blood pressure 
and venous return. The heart regulates cardiac output by changes in contractility, heart 
rate, and loading conditions. The resistance circuit is responsible for increases and 
decreases in vascular resistance, alterations in cardiac load conditions, blood pressure, 
and distribution of blood flow.  Heterogeneity of arteriolar tone between different organs 
causes maldistribution of blood flow and local mismatch between oxygen demand and 
supply.  49,62,76 The fourth and fifth components are the capillaries and the venules. 
Alterations in the permeability or cross-section of the capillaries may cause severe 
impairment of tissue oxygenation. Bypass of capillaries by opening of arteriovenous 
shunts contributes to tissue hypoxia during shock. 49,76 The venules are most prone to 
occlusion during changes in rheology. Increases in venular tone may then lead to 
increased extravasation in the capillary network.  49,76 The venous capacitance circuit, in 
which 70–80% of the total blood volume resides, is the sixth component. A decrease in 
venous tone leads to impairment of venous return, while an increase in venous tone leads 
to enhancement of venous return. Mainstream patency forms the last component. 
Obstruction to both arterial and venous blood flow causes impediments to either 
ventricular ejection or venous return. 54,76 
 
In circulatory shock, the underlying diseases or causes may vary widely. 64 
Derangements in any of the components of the circulatory system may lead to circulatory 
failure, which if its allowed to proceed without timely intervention, ultimately will lead to 
the common picture of shock. Changes in macrohemodynamics may lead to impaired 
microcirculatory perfusion of the tissues. 78 In certain types of shock, microvascular 
derangements seem to precede macrovascular alterations. 79 Derangements on the 
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microcirculatory level may persist despite stabilization of the macrocirculation. 80 Hence, 
changes in the microcirculation seem to be of even greater importance in the development 
of failure of tissue oxygenation than changes in the macrocirculation.  51 	  
For a more detailed description of the different underlying pathophysiologies, the four 
main categorical types of shock may be further divided into two categories, hypodynamic 
shock (cardiogenic, obstructive, and hypovolemic) and hyperdynamic shock, due to 
pathophysiological similarities.  76 Vasodilatory shock is a final common pathway of long-
lasting and severe shock of many causes.  81 
 	  	  	  
	  
 
 
Figure 5. Common pathway of shock. 	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2.3.1. PATHOPHYSIOLOGY OF HYPODYNAMIC SHOCK  
 
The central features of hypodynamic shock are low cardiac output and vasoconstriction.  
 
When tissue perfusion is reduced to a critical level because of a reduction in cardiac 
output due to loss of blood volume, loss of pump function, or obstructed flow, a set of 
compensatory reflexes is elicited. The sympathetic system is activated to compensate for 
the reduced tissue perfusion, increasing heart rate and contractility. As a result, 
catecholamines, angiotensin, vasopressin, and endothelins are released. 76,82 These 
substances cause vasoconstriction, shifting the blood from the capacitance circuit 
(unstressed volume) to the central circulation (stressed volume), thereby causing a 
(temporary) compensatory increase in venous return.  76 Blood flow is directed away from 
muscles and the splanchnic area towards the brain and the heart. Water and sodium 
retention is enhanced by release of vasopressin and activation of the renin-angiotensin 
system.  
 
As the shock state worsens, blood pressure decreases further and coronary perfusion 
is impeded, compromising cardiac function. As vasoconstriction increases further, the 
weakened myocardium encounters yet another increase in afterload, further impairing 
cardiac function. The terminal phases of shock are characterized by an increase in 
microvascular permeability due to changes in capillary hydrostatic pressure. Leukocytes 
adhere to the endothelial walls and concomitant changes in red blood cell rheology 
facilitate platelet adhesion. This chain of events ultimately leads to the blocking of 
capillary beds and progression of tissue hypoxemia. The process is accelerated by the 
release of systemic mediators of inflammation. Upon progression of the cascade of shock 
to this point of “no-reflow” and end-organ damage, irreversible hypoperfusion, 
hypotension, and death will inevitably follow.  64,76,82 
 
 
 
2.3.2 PATHOPHYSIOLOGY OF HYPERDYNAMIC SHOCK 
 
The central features of hyperdynamic shock are high cardiac output (CO) and 
vasodilation, with derangements in microcirculation and oxygen utilization. 
 
Hyperdynamic shock, particularly septic shock, is characterized by the release of 
inflammatory mediators in the bloodstream in reaction to exogenous agents. This 
profoundly complex pro-inflammatory cascade is triggered by severe microbial infection 
or extensive tissue damage. Activation of the complement system and hyperactivation of 
the cellular innate immune system lead to an excessive inflammatory response. 
Neutrophils and macrophages then react to the initial inflammatory stimuli of released 
cytokines, such as interleukin-1β, interleukin-6, tumor necrosis factor- α (TNF-α), 
interferon-γ, chemokines, and complement activation products, resulting in the release of 
secondary mediators (lipid factors and reactive oxygen species). 76,83,84 This complex 
cascade leads to arterial and venous vasodilation and a concomitant increase in cardiac 
output. The influence of vasodilatory substances, such as nitric oxide (NO), predominates 
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over endogenous and exogenous vasopressor agents. Vasodilation may also be enhanced 
by inappropriately low levels of vasopressin or cortisol, producing vascular 
hyporesponsiveness to catecholamines. 81,85 Limitations of nutrient flow develop as a 
result of blocking of the capillaries due to adhesion of activated leukocytes and platelets to 
the endothelium, in interplay with the activated coagulation cascade.  The terminal phase 
of hyperdynamic shock is characterized by refractory hypotension, worsening tissue 
hypoperfusion, acidosis, and hypodynamic circulation.  76 
 
 
 
2.3.3 PATHOGENESIS OF VASODILATORY SHOCK 
 
In septic shock, as well as in prolonged and severe hypotension caused by cardiogenic or 
hemorrhagic shock, the clinical picture is dominated by excess vasodilation. 81 
 
Despite differences in the mechanisms of vasodilation depending on the underlying 
condition, some important common mechanisms exist. Vasoconstriction requires the 
binding of a ligand, such as angiotensin or norepinephrine, to the surface receptors of the 
vascular smooth muscle cell.  76,81,82 Through actions of second messengers, calcium is 
released from intracellular stores and the calcium level in the cytosol is increased. 
Calcium then binds to calmodulin, which activates a kinase that phosphorylates myosin. 
This enables activation of myosin ATPase by actin and subsequent contraction of the 
smooth muscle. Vasodilators, such as nitric oxide (NO), lead to the dephosphorylation of 
myosin, thus preventing contraction.  81 
 
The membrane potential and more specifically the ion transporters and channels of 
the plasma membrane of the muscle cells also play a crucial role in vasodilation and 
vasoconstriction. Hyperpolarization of the plasma membrane prevents calcium influx and 
constriction. The KATP-channels allow efflux of potassium, thus depolarizing the 
membrane. Pharmacologic activation of these channels therefore inhibits 
vasoconstriction. These channels are activated by low cellular energy levels (ATP) and 
high levels of H+ and lactate under physiological conditions, thus connecting metabolism 
with vasodilation and blood flow.  81 
 
Increased synthesis of NO contributes to vasodilation and hyporesponsiveness to 
vasopressors in vasodilatory shock. In septic and decompensated hemorrhagic shock, the 
production of NO is increased due to inducible nitric oxide synthases (iNOS). The 
vasodilating effect of NO is probably mainly mediated through the activation of myosin 
light-chain phosphatase. Resistance to vasopressor agents is mostly a consequence of NO-
induced activation of calcium-sensitive potassium channels, leading to hyperpolarization 
of the plasma membrane in smooth muscle cells.  81,86 
 
Vasopressin levels rise in septic and hemorrhagic shock as a consequence of baroreflex 
activation. Normally vasopressin plays only a minor role in arterial pressure regulation, 
but during hypotension and shock it is released from the neurohypophysis. As shock 
worsens, vasopressin levels decrease, however, probably due to depletion of vasopressin 
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stores in reaction to massive stimulation. Correction of these inappropriately low levels of 
vasopressin raises blood pressure in patients with hemorrhagic and septic shock, as well 
as in organ donors and patients who have suffered from cardiac arrest and are refractory 
to vasopressor treatment.  81,87 
 
 
 
2.3.4 MICROCIRCULATORY CHANGES DURING SHOCK 
 
The main prerequisite for adequate tissue oxygenation and end-organ function is 
preserved microcirculatory function. 79,88 The microcirculation consists of the smallest 
blood vessels in the body, with a diameter of 100 µm or less, and its main purpose is to 
transport oxygen and nutrients to the cells. The microcirculation is regulated by 
myogenic, metabolic, and neurohumoral mechanisms. During sepsis severe 
derangements of these regulatory mechanisms occur. 79,88 
 
A main feature of the pathogenesis of distributive shock is shunting of oxygen 
transport to the tissues. 79 Septic microcirculatory dysfunction is characterized by a 
heterogeneity of capillary blood flow. Some capillaries are underperfused, while others 
are normoperfused.  89 Vulnerable microcirculatory units become hypoxic, and the partial 
pressure of oxygen drops below the level of venous blood. This gap in oxygen tension is 
more severe in sepsis than in hemorrhagic shock and cannot be measured by monitoring 
parameters of systemic hemodynamics. 79 In sepsis and distributive shock, signal 
transduction pathways are deranged. Incapability of endothelial cells to perform 
regulatory function follows. In addition, nitric oxide (NO) is produced by inducible nitric 
oxide synthases (iNOS), further aggravating the microvascular dysfunction by increased 
shunting of blood flow. Some areas express less iNOS, which renders these areas prone to 
hypoperfusion. 75 Abnormalities in the nitric oxide system are one of the key features of 
distributive shock.  90 
 
In addition to these changes, alterations in both erythrocytes and leukocytes occur. 
Erythrocytes become more rigid and undeformable, increasing the likelihood of 
aggregation. Leukocytes induce an array of inflammatory mechanisms by which they alter 
cellular interactions and coagulation as well as disrupt structures of microcirculation, 
ultimately leading to tissue edema. 79,88 
 
While the microcirculation seems to be the driving force in septic shock, experimental 
data reveal that in hemorrhagic shock microcirculation follows macrocirculation.  78 In 
hemorrhagic shock, microcirculatory variables were closely related to macrocirculatory 
parameters also during the resuscitation phase. Moreover, the microcirculation of the gut 
was found to be far more susceptible to blood loss than the heart. 78 In septic shock, 
parameters describing microcirculation have not been shown to improve despite 
successful restoration of macrocirculation.  80 
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2.3.5 CHANGES IN OXIDATIVE METABOLISM DURING SHOCK 
 
When global distribution of blood flow is decreased or there is regional 
maldistribution of blood flow at the macrovascular or microvascular level, impairment of 
oxidative metabolism follows. Though oxygen consumption may be increased in the 
initial phases of shock, all types of shock eventually lead to a decrease in oxygen 
consumption. Data from experimental studies, some of which were conducted nearly half 
a century ago, show that adverse outcome was directly related to the degree of total 
accumulated oxygen debt. 76,91 
 
In normal circumstances, oxygen consumption (VO2) is independent of oxygen 
delivery (DO2). During a decrease in cardiac output a compensatory increase in oxygen 
extraction from a normal level of 25% to a maximum level of 80% takes place and oxygen 
consumption remains unaltered. When oxygen extraction is maximized, a critical level of 
DO2 is reached, below which VO2 is totally dependent on DO2. Further decreases in DO2 
lead to decreases in VO2 and a need for anaerobic metabolism. 76,92 In critical illness, 
alterations caused by medication or septic changes in vasomotor reflexes lead to critical 
tissue hypoxia at lower levels than during normal physiological conditions.  76 
 
During tissue hypoxia there is a deficit of oxygen, which is mandatory for oxidative 
phosphorylation in the mitochondria. In anaerobic conditions, cells have to manage on 
two molecules of adenosine triphosphate (ATP) per molecule of glucose generated during 
glycolysis in the cytoplasm, in contrast to the 38 molecules of ATP generated under 
aerobic conditions. Also under anaerobic conditions, pyruvate cannot enter the citric acid 
cycle. Instead it is turned into lactate, which cumulates as a sign of deficits in cellular 
energy metabolism.  46,76 
 
In addition to the mechanisms elicited by decreases in blood flow, other mechanisms 
are responsible for worsening of oxidative metabolism. Several inflammatory mediators, 
such as NO, endotoxin, oxygen radicals, and tumor necrosis factor-α (TNF-α), impair 
mitochondrial function, as shown in animal studies of septic shock and reperfusion 
injury. 93 Serum from patients with septic shock has been demonstrated to inhibit 
mitochondrial respiration in experimental studies. 94 Secondary to a period of cellular 
dysoxia due to microvascular derangements, mitochondrial function becomes impaired. It 
is not clear whether this phenomenon is reversible, but if so it is assumed that the 
reversibility is time-dependent. This impairment of both the microcirculatory and 
mitochondrial functions has been defined as the microcirculatory and mitochondrial 
dysfunction syndrome (MMDS).  79 
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2.4 EPIDEMIOLOGY AND INCIDENCE OF HEMODYNAMIC 
FAILURE IN CRITICAL ILLNESS  
 
 
2.4.1 EPIDEMIOLOGY AND INCIDENCE OF HEMODYNAMIC FAILURE 
IN THE CRITICALLY ILL 
 
Hemodynamic failure is frequently encountered in critically ill patients. 48 Few studies 
have, however, assessed the overall incidence of hemodynamic failure in critically ill 
patients. The overall incidence of shock was 33.6% in a large study comprising 198 
European intensive care units (ICUs).  95 Of these patients, 80% received norepinephrine 
for hemodynamic support.  In this large European multicenter study (SOAP), 36% of 
patients without sepsis and 63% with sepsis had hemodynamic failure.  In 8% versus 14% 
of these patients hemodynamic failure presented as a single, isolated organ failure. Of a 
total of 3147 patients, 462 (15%) were diagnosed with septic shock.  95,96  
In the large multicenter prospective study by Vincent and collaborators exploring the 
usefulness of SOFA score for assessing organ dysfunction and failure, the association 
between organ dysfunction and outcome was evaluated. The study was conducted in 40 
ICUs located in 13 European countries, in addition to Brazil, Canada, and Australia in the 
late 1990s. For a total of 1449 patients with a variety of indications for admission, 
including elective surgery, the subscore for cardiovascular organ dysfunction was 
assessed as part of the total SOFA score. The cardiovascular subscore was elevated, 
indicating some degree of hemodynamic failure at the time of admission of 29% of the 
patients.  97 
 	  
2.4.2 EPIDEMIOLOGY AND INCIDENCE OF SEPTIC SHOCK 
 
In previous epidemiological studies of sepsis, severe sepsis, and septic shock, the 
occurrence of septic shock in patients diagnosed with severe sepsis has ranged from 46% 
to 77%. 98,99 In the Finnsepsis study, which was conducted in 24 Finnish ICUs during four 
months in 2005, the total incidence of severe sepsis was 0.38/1000 in the adult Finnish 
population.  During the study period 470 patients of a total of 4500 consecutive ICU 
admissions had severe sepsis and 77% of these developed septic shock. 10,100 In a 
prospective observational study comprising 24 Italian ICUs, the incidence of septic shock 
was 33% in patients with sepsis and approximately 4% in the total ICU patient 
population.  98 In these studies, the main sources of infection were the lungs, abdomen, 
skin or soft tissue, and the urinary tract.  10,98 
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2.4.3 EPIDEMIOLOGY AND INCIDENCE OF OTHER TYPES OF SHOCK 
IN THE CRITICALLY ILL 
 
Hemorrhagic shock continues to be a leading cause of mortality, accounting for 30-40% 
of trauma-related deaths. Trauma is the leading cause of death in patients younger than 
45 years in the USA. 101 Of all deaths caused by injury, 50% occur at the site of the 
accident, 30% during the first 24 hours, and 20% later due to multiple organ dysfunction 
(MOD).  101 Exact data on the incidence of hemorrhagic shock in patients admitted to 
hospital due to hemorrhage are, however, scarce. In a study from a trauma center in San 
Diego, hypovolemic shock was present in 13.1% of the 466 patients who had not received 
cardiopulmonary resuscitation prior to hospital admission.  102 Even after initial survival, 
patients suffering from hypotension due to hemorrhagic shock are at risk for acidosis, 
sepsis, and multi-organ dysfunction. 103  	  
The incidence of cardiogenic shock in Finland has not been studied. 104 The incidence 
of cardiogenic shock in the United States is approximately 40 000 to 50 000 cases per 
year. 66 Cardiogenic shock complicates approximately 5-8% of ST-elevation myocardial 
infarctions (STEMI), which are the leading cause for cardiogenic shock. In recent years, 
the prevalence has decreased due to early intervention and reperfusion therapies.  66,105  
 
In a Chinese study assessing the incidence of organ failure associated with severe 
acute pancreatitis (SAP), cardiovascular failure as a single organ failure or as part of a 
multiple organ failure was reported in 18% of the patients. 39 In the Finnish study by 
Halonen and collaborators, 80% of SAP patients managed in ICUs showed at least some 
degree of hemodynamic compromise, deduced from elevated cardiovascular SOFA scores 
during their ICU stay. 106 	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2.5 ORGAN MANIFESTATIONS IN SHOCK   
 
Hemodynamic failure or shock itself is often defined as an organ failure. Several of the 
severity scoring systems that are utilized in critical care have a subscore for describing 
cardiovascular function.  97,107,108 Higher scores have been associated with worse outcome 
in ICU patients. 97,108-110 The development of organ failure in association with 
hemodynamic failure has been most extensively studied in hemorrhagic and septic shock. 
The association of hypoperfusion with organ failure or postoperative complications has 
also been assessed.  111,112 
 
 
2.5.1 KIDNEY 
 
When assessing a patient in shock, urine output provides a means of looking at the 
circulation. 63 Persisting but not transient oliguria is predictive of development of new 
acute kidney failure, especially in the face of increasing vasopressor requirements and 
hemodynamic instability. 113 The pathophysiology of AKI during shock is, however, 
somewhat unclear. The mechanisms leading to injury have mainly been studied in 
experimental animal models or through indirect evaluation of kidney function, as 
repetitive renal biopsies of critically ill patients would not be ethically justifiable. 114 
Studies of hypodynamic shock (hypovolemic, hemorrhagic, and cardogenic shock) have 
suggested that a deterioration of renal perfusion, leading to ischemia and subsequent re-
perfusion injury, is the main pathophysiological mechanism responsible for the 
development of AKI during hemodynamic failure.114,115 This also holds true for 
postoperative AKI, which predominantly is considered to be a consequence of transient or 
persisting renal ischemia. 116 Complete renal ischemia and re-perfusion have clearly been 
associated with AKI in clinical and experimental studies.115 Somewhat contradictorily, 
temporary occlusion of the renal artery or global ischemia caused by cardiac arrest has 
only been shown to cause transient changes in renal function. 117,118 
 
Acute kidney injury due to septic shock seems to evolve in a slightly different setting. 
Results from experimental studies concerning renal blood flow during septic shock have 
been inconsistent. In a systematic review of 160 experimental studies of AKI in sepsis, 
renal blood flow was increased in about 30% of the studies, and the only predictor of low 
renal flow was low cardiac output.  119 Evidence exists that auto-regulation of renal blood 
flow is impaired in critical illness before and during AKI, rendering renal blood flow 
dependent on cardiac output. During hyperdynamic sepsis AKI may develop in a setting 
of high renal blood flow. 119,120 In an experimental study of conscious sheep, Langenberg 
and coworkers showed that the development of AKI during septic shock is associated with 
an increase in renal blood flow and a decrease in vascular resistance, which subsequently 
leads to a marked decrease in glomerular filtration and an increase in serum creatinine. 121 
Data from another experimental study implied that renal recovery was associated with a 
decrease in cardiac output, an increase in vascular resistance, and a decrease in renal 
blood flow.  122 Based on experimental data, it seems that AKI associated with septic shock 
may be of hyperemic origin. 114,121,122 Dilation of afferent arterioles and a more pronounced 
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dilation of efferent arterioles of the kidney lead to an increase in blood flow, with a 
concomitant decrease in glomerular filtration rate.  114 
 
Recent evidence suggests, however, that the development of AKI during shock is not only 
a question of blood flow and perfusion. Some evidence has emerged that AKI develops 
due to inflammatory derangements in the microcirculation, with subsequent capillary 
leak and intrarenal shunting, and that pro-inflammatory cytokines and NO play an 
important role in this process. 115,123,124 The decrease in blood flow and renal perfusion may 
not be a prerequisite for but rather the consequence of a complex cascade of 
inflammatory and microvascular events taking place during the early phases of AKI.  115 
To further complicate the issue of hemodynamics and AKI, treatment and prevention of 
this frequent phenomenon in the critically ill still rely on optimal restoration of 
macrohemodynamics and accurate fluid restoration. 115,125 Evidence exists that an increase 
in systemic blood pressure increases glomerular filtration. 44 There is also some evidence 
from studies of septic AKI that lower blood pressure levels are associated with 
development or progression of AKI. 126,127  
 
 
2.5.2 BRAIN 
 
Several neuropathological alterations take place during shock. 128,129 Changes in 
consciousness and mentation are common clinical findings in all types of shock. These 
changes provide the clinician with another means of looking at the circulation. 63 Cerebral 
oxygen function accounts for approximately 20% of total resting body oxygen 
consumption. The high metabolic demand must be met, and as the brain is unable to 
store energy, high blood flow is required.  Cerebral blood flow accounts for about 20% of 
the total cardiac output, of which 90% is needed for brain function and 10% for cell 
viability.129 Under physiological circumstances, the mechanisms of cerebral 
autoregulation are able to maintain a relatively constant cerebral blood flow within a 
range of mean arterial pressure (MAP) from 60 to 150 mmHg. 129 There is evidence, 
however, that critical illness and sympathetic activation impair autoregulation, and 
cerebral blood flow becomes dependent on systemic blood flow also within the normal 
ranges of autoregulation. In an experimental model of anaphylactic shock in rats, 
Davidson and collaborators found that cerebral blood flow decreased linearly with a 
decrease in MAP, thus impeding cerebral oxygenation. The decrease in cerebral flow was 
moreover not fully corrected by volume expansion. In an experimental study in sheep 
with septic shock, the findings were similar, indicating severe impairment of cerebral 
blood flow and microcirculatory derangement, especially in the early stages of shock.  130 
The findings of two earlier experimental animal studies of hemorrhagic and cardiogenic 
shock, on the other hand, indicated preserved cerebral perfusion under these 
conditions.131,132 
 
The differences in preservation of cerebral flow may be accounted for by the different 
inflammatory profiles of the different shock types. 133 In a canine experimental study of 
cardiac arrest, the microcirculation was severely altered after restoration of spontaneous 
circulation and did not correlate with macrohemodynamic measurements.  134 There are 
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also data from studies in patients with septic shock that vasomotor reactivity is disturbed 
during septic shock, causing detrimental changes in microcirculation and perfusion. 135 
These alterations in cerebral blood flow and microcirculation have been proposed to be 
attributable to septic encephalopathy (SAE), a diffuse form of cerebral dysfunction, often 
encountered in critically ill patients.128,135 The neuropathological correlates of septic 
encephalopathy have not been extensively investigated. 136 In a study by Sharshar and 
coworkers focusing on the neuropathology of patients who had died of septic shock, signs 
of ischemia were present in all patients. It was more pronounced in autonomic centers in 
patients with septic shock than in patients who had died of other causes and was more 
often associated with apoptosis. Also, in these patients, levels of intravascular iNOS were 
significantly higher than in other patients, while levels of TNF-α did not differ.  136,137 In a 
recent study, magnetic resonance imaging revealed high incidences of 
leukoencephalopathy and ischemia in patients with septic shock. These findings were 
associated with adverse outcome. 138  
 
 
2.5.3 GUT, LIVER, AND PANCREAS 
 
“Shock bowel”, or “hypoperfusion complex”, is a term used to describe findings in 
abdominal computed tomography scans of patients in severe hypovolemic shock, often 
due to trauma and hemorrhage.139 The “hypoperfusion complex” entails abnormally 
intense contrast enhancement of the bowel wall, mesentery, kidneys, and pancreas; 
decreased caliber of the abdominal aorta and inferior vena cava; and moderate to large 
peritoneal fluid collections. This entity was first presented by Taylor and collaborators in 
the late 1980s and was associated with poor outcome. 140 The intestinal mucosa is affected 
during hemorrhagic shock, resulting in significant local inflammation, damage of the 
enterocytes and the gut barrier function, and translocation of mediators and pathogens 
from the gut lumen to the surrounding tissues. 103 The intestine has been suggested to 
play a central role in the development of shock by being a primary source of inflammatory 
mediators. 141 An experimental animal study revealed that inflammatory mediators are 
secreted into the gut lumen during hemorrhagic shock, where they interact with the 
endothelial cells in a paracrine fashion.  103 During ischemia or reduced integrity of the gut 
wall pancreatic enzymes may penetrate the gut and become systemic, triggering 
circulatory shock.  142 
 
In an animal study of intestinal microcirculation during hemorrhage, microcirculatory 
flow decreased proportionly to the decrease in systemic flow in the gastric and colon 
mucosa as well as in the liver and the kidney. However, the pancreatic flow decreased 
more than the systemic blood flow, implying that the pancreas is particularly susceptible 
to hemodynamic failure.  143 Earlier studies indicate that splanchnic hypoperfusion during 
shock, or hypoperfusion during cardiac bypass operations, may lead to pancreatitis.  
Pancreatitis is then further aggravated if hypoperfusion persists, as is the situation during 
postoperative low cardiac output. There is also evidence that temporary ischemia renders 
the pancreas more vulnerable to digestive enzymes.18 If pancreatitis follows, 
hemodynamic failure may be further aggravated due to the release of inflammatory 
mediators.  144 
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Ischemia during or after hemorrhagic shock may cause hepatic injury. The ischemic 
stress is plausibly mediated by an array of inflammatory mediators, leading to 
microcirculatory dysfunction, leukocyte infiltration, cell membrane damage, impaired 
biliary flow, and fibrosis. 145 Strong evidence indicates that cardiogenic shock or cardiac 
failure may cause hepatic injury through mechanisms of hypoperfusion. 146 Septic shock is 
also one of the most common etiologies for hepatocellular injury in the ICU. 147 
 
 
2.5.4 COAGULATION 
 
In the pathogenesis of sepsis, inflammation and coagulation play crucial roles. Increasing 
evidence indicates that inflammation activates coagulation, and coagulation reciprocally 
affects inflammation. 148 The majority of critically ill patients with systemic inflammatory 
response have coagulation abnormalities, ranging from subtle, hardly detectable ones to 
fulminant disseminated intravascular coagulation (DIC). 148 During sepsis and septic 
shock several mechanisms contribute to alterations in coagulation. The most important 
underlying mechanism is thrombin formation mediated by tissue factor. 148,149 When the 
integrity of vessel walls is disrupted, or when circulating cells or endothelial cells are 
exposed to cytokines, most importantly IL-6, expression of tissue factor follows.  Tissue 
factor then comes into contact with blood, leading to activation of the coagulation 
cascade. 148 During inflammation-induced activation of coagulation the three most 
important anticoagulant pathways may also be impaired. First, during severe 
inflammatory response, the antithrombin (AT) levels are markedly decreased, partly due 
to impaired synthesis. Second, the protein C system malfunctions at all levels. Third, the 
function of tissue factor pathway inhibitor (TFPI) seems to be impaired during severe 
inflammation, further aggravating the imbalance between coagulation and 
anticoagulation. 148,149 	  
In hemorrhagic shock, coagulopathy is closely linked to the underlying trauma and the 
trauma mechanism, and to the degree of blood loss and the subsequent fluid 
resuscitation. Tissue factor plays an important role also in activating coagulation due to 
trauma and blood loss by binding to factor VII, and thus, initiating the coagulation 
cascade. During hemorrhage, DIC may be caused by excessive formation of thrombin and 
fibrin concomitant with excessive consumption of platelets and coagulation factors. 150 It 
appears that hypoperfusion is essential for the development of coagulopathy during 
trauma and hemorrhage. Tissue injury induces thrombin formation, which in 
combination with shock-induced hypoperfusion results in increased activation of 
thrombomodulin (TM), leading to development of coagulopathy. The protein C system 
seems to play a role also in the development of coagulopathy during hemorrhagic shock 
by causing both impaired clot formation and enhanced lysis of the formed clot. 151 In 
traumatized patients with hemorrhagic shock, coagulopathy may also arise at a later 
stage. Factors that have been associated with coagulopathy at this later stage include 
acidosis, hypothermia, and excessive hemodilution. 150 
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2.5.5 LUNG 
 
In adult respiratory distress syndrome (ARDS) of inflammatory origin, the vascular 
endothelial cells play a pivotal role. These cells constitute a multifunctional monolayer of 
cells, which play an important part in regulating vascular tone, coagulation, and immune 
responses. In extrapulmonary injury, such as sepsis, trauma, and hemorrhage, activation 
of the endothelial cells leads to generation of reactive oxygen species and release of an 
array of inflammatory mediators, which cause increased vascular permeability and 
sequestration of neutrophils, ultimately leading to ARDS. 152 
 
There is now increasing evidence of the association of ARDS and multi-organ 
dysfunction (MOD) with the mesenteric lymphatic route during hemorrhagic shock. 
Patients who have been resuscitated from severe hemorrhagic shock often develop 
systemic inflammatory response syndrome (SIRS). These patients may develop ARDS and 
MOD, which may lead to death. Evidence now exists that the mesenteric lymphatic route 
is essential for the transport of factors that lead to distant organ injuries. Animal studies 
have shown that ligation of the mesenteric lymphatic duct can abrogate the progression of 
the organ injuries normally seen in post-hemorrhagic animals.  153,154 	  
2.5.6 HEART 
 
In cardiogenic shock, failing pump function is a prerequisite for circulatory failure. 66,105,155 
Cardiac function is often altered secondary to circulatory failure also in shock types of 
other origin.  
Established hemorrhagic shock ultimately leads to anaerobic metabolism, ischemia, and 
frequently cardiac failure. 156 In hemorrhagic shock, the ischemic disorder is induced by 
impaired perfusion of organs due to hypovolemia. The disorder may be further 
aggravated by reperfusion injury as a consequence of blood transfusion and fluid 
therapy.157 Organ injury is thought to be mediated by cytotoxic cytokines, lysosomal 
enzymes, and free radicals, which are released during prolonged ischemia and 
reperfusion. In addition, direct deleterious effects of lysosomal enzymes cause 
mitochondrial dysfunction, further impairing cardiac function. 157  
 
Increasing evidence is emerging for the gut playing a crucial role in the pathogenesis 
of SIRS and MOD following shock. Previously, bacterial translocation was considered 
essential for this process. Recently, however, it has been shown that non-bacterial factors 
from the intestine egress into the mesenteric lymph, leading to the development of post-
shock organ failure. 154 The underlying mechanisms seem to involve the interaction of 
pancreatic enzymes with the ischemic gut. Interestingly, mesenteric lymph generated 
during burn injury causes changes in myocardial contractility. Astonishingly, cardiac 
contractile dysfunction was prevented by mesenteric lymph duct ligation in rats subjected 
to hemorrhagic shock. 154 
 
One of the key findings of myocardial dysfunction in septic shock came from the group 
of Parrillo in 1984. 158 The classic study by Parker and coworkers showed that 15 of 20 
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patients with septic shock had depression of the left ventricle in terms of left ventricular 
ejection fraction (LVEF) during the first two days. All 20 patients had high CO and low 
systemic vascular resistance (SVR). The most interesting finding was that survivors had 
low LVEF for four days, after which it slowly returned to normal by days 7-10. The low 
LVEF was combined with reversible left ventricular dilatation, also normalizing in 7-10 
days. 158,159 These findings of evident systolic deterioration, being worst on day 2 and 
recovering after day 3-4, finally reaching normal values in a week have been confirmed in 
many studies. 158 In a prospective echocardiographic study by Vieillard-Baron and 
coworkers, the incidence of left ventricular (LV) systolic function in patients with septic 
shock was 60%, as defined by LVEF < 45%.160 Patients with septic shock also have 
depressed response to volume expansion, as shown by Ognibene and collaborators.  161 
During the last decade there has been increasing interest in diastolic dysfunction during 
septic shock. In a recent fairly large prospective study of patients with severe sepsis or 
septic shock, the incidence of isolated LV systolic dysfunction was 9%, combined systolic 
and diastolic dysfunction 14%, and isolated LV diastolic dysfunction 38%. In this study, 
diastolic dysfunction was the strongest predictive factor for mortality, also after 
adjustment for confounding factors. 162 Similar results have been demonstrated earlier by 
the groups of Sturgess and Ikonomidis. 163,164 
 
As for the underlying mechanisms of myocardial dysfunction during septic shock, it 
was believed for decades that reduced coronary blood flow was the primus motor of septic 
myocardial dysfunction. This was, however, proved incorrect in direct studies of blood 
flow and metabolism in the 1980s. 158 A decade earlier, Wangensteen and coworkers 
suggested that myocardial depression was due to a circulating myocardial depressant 
factor. Parillo later showed that serum obtained from patients suffering from septic shock 
actually caused changes in cardiomyocytes in vitro, an effect most likely caused by 
circulating cytokines. Nonetheless, myocardial depression lasts longer than the “cytokine 
storm”, and currently cytokines are thought to participate in the initial events leading to 
prolonged septic cardiomyopathy. 158 This prolonged phase of myocardial dysfunction is 
believed to be further aggravated by several intrinsic mechanisms of the myocardium, 
including alterations in the beta-adrenergic pathway, decreased response of myofilaments 
to calcium, production of NO and peroxynitrite, and cell death and apoptosis. 158 
Scmittinger and coworkers recently conducted a post-mortem study of hearts of patients 
who had died of septic shock. One-fifth of the patients had non-occlusive cardiac 
ischemia, a typical finding in patients suffering from an imbalance in supply and 
consumption of oxygen, which is frequently seen in states of high sympathetic tone. 
Nearly all patients had contraction band necrosis, which is caused by irreversible 
hypercontraction of the myocytes. This finding, which is the hallmark of 
pheochromocytoma, is also frequently referred to as catecholamine necrosis and can be 
caused experimentally by infusion of catecholamines. This recent finding emphasizes the 
importance of stress-induced changes in shocked hearts.165                        
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2.6. HEMODYNAMIC MONITORING 
 
 
Hemodynamic assessment and monitoring play a fundamental role in the management of 
the critically ill patient with hemodynamic failure.166-168 Monitoring of critically ill patients 
usually entails use of several monitoring methods, including clinical assessment of vital 
signs. Hemodynamic monitoring is used in the ICU to identify cardiovascular failure or 
insufficiency by assessing isolated values as well as trends of values over time.  
Hemodynamic monitoring also provides information needed to identify the probable 
cause and is equally important in assessing response to therapy. 169 	  
The ultimate aim of hemodynamic monitoring is to measure whether the circulation 
provides sufficient and adequate oxygen supply to meet the prevailing oxygen demand. 170 
It must be emphasized that no means of monitoring or the monitoring device itself can 
improve outcome, unless accompanied by effective treatment. 169 Conducting studies for 
comparative evaluation of different methods of hemodynamic monitoring with outcome 
endpoints is challenging, as outcome depends not only on monitoring, but also on the 
treatment provided. 168 Furthermore, interpretation of values achieved relies on the skills 
and experience of the attending physician. During the past 50 years hemodynamic 
monitoring has developed rapidly. There is now a wide range of available methods for 
hemodynamic evaluation, from highly invasive methods to mini-invasive or completely 
non-invasive ones. The focus has turned from static measures to dynamic ones, but 
despite this development and the numerous experimental and clinical studies, it is still 
unclear whether the choice of hemodynamic monitoring matters. 168 Traditionally, 
hemodynamic monitoring has focused on macrohemodynamic indices.  Lately, 
monitoring of the microcirculation has attracted much interest, as its importance in the 
development and pathophysiology of shock has been established.171 
 
 
 
2.6.1 MEAN ARTERIAL PRESSURE 
 
Basic monitoring of the critically ill patient has included invasive measurement of blood 
pressure, particularly mean arterial pressure (MAP). Although hypotension is not an 
absolute requirement for identifying shock according to some of the definitions 
provided,172 it frequently accompanies shock and is a prerequisite for the current 
definition of septic shock. 173 MAP is an important parameter for assessing adequacy of 
macro hemodynamics and response to fluid and vasopressor therapy. Monitoring and 
targeting values for MAP constitute an essential part of current treatment guidelines for 
septic shock.  35,174,175 Results from previous studies indicate that maintaining MAP at 60-
65 mmHg has beneficial effects on outcome. 176 Sufficient perfusion pressure of end 
organs is pursued by preserving adequate blood pressure.  MAP, in addition to other 
hemodynamic parameters, such as heart rate, cardiac output, central venous pressure, 
and pulmonary artery occlusion pressure (PAOP), can also be used for differentiating 
types of shock.  169 
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2.6.2 STATIC PRELOAD MEASURES, MIXED VENOUS OXYGEN 
SATURATION, AND CARDIAC OUTPUT 
 
Central venous pressure (CVP) and PAOP are static indices of preload, meaning that they 
measure the pressure within a chamber in relation to the atmosphere. For five centuries, 
CVP has been frequently monitored and utilized in the ICU to describe the pressure of the 
right atrium and indirectly the cardiac filling pressure and preload status. 177-179 CVP 
accurately describes the pressure in the right atrium when no obstruction of the venae 
cavae exists. 177 CVP is, however, dependent on cardiac function, and a specific or isolated 
value of CVP has little predictive value for fluid responsiveness. 37,180 In a systematic 
review of 24 studies, Marik and coworkers found that there was no association between 
CVP and the circulating blood volume, and that CVP could not predict fluid 
responsiveness. 179 However, CVP may provide important information and aid the 
clinician in decision-making and hemodynamic profile analysis 169 once the basic 
principles and the restrictions for its use are understood.  178 	  
The pulmonary artery catheter (PAC) provides the clinician with right (CVP) and left 
side (PAOP) filling pressures as well as with pulmonary artery pressures. In addition, it 
provides a means of cardiac output (CO) measurement through thermodilution and the 
possibility to continuously measure mixed venous oxygen saturation (SVO2). The 
introduction of the balloon-tipped catheter in 1970 181 brought a powerful tool for semi-
continuous hemodynamic monitoring to the ICU and provided data that previously was 
available only in catheterization laboratories. 171,182 In clinical studies, the filling pressures 
obtained by use of PACs have not been found to predict fluid responsiveness, and thus, 
the PAC is not optimal for assessing preload status.37 Many studies have assessed 
potential advantages and disadvantages of the PAC in different patient populations182 
since the first large retrospective study by Connors and coworkers that indicated higher 
mortality and higher costs of treatment. 183 Based on a multitude of retrospective and 
prospective clinical trials, however, the use of the PAC is not associated with any change 
in mortality and morbidity.182,184 Due to its invasiveness, lack of unquestionable 
superiority, and the continuing development of other less invasive, but equally accurate 
means of hemodynamic measurement, the popularity of PACs has declined in recent 
years. 185 Nevertheless, the PAC may still provide invaluable information in diagnosis and 
assessment of response to treatment in cardiac conditions and refractory shock, and 
although not indicated for the general ICU population, it should not be forgotten. 185-187 
 
CO measurement by thermodilution using the PAC is still considered the “gold 
standard” and continues to serve as a reference for newer less invasive methods of cardiac 
output monitoring. 188 Measurement of CO is not currently advocated in the treatment of 
all patients with shock, but it is recommended in the treatment of patients with evidence 
of ventricular failure or refractory shock. 172 Although several mini-invasive and entirely 
non-invasive methods have been presented in recent years showing feasibility and fairly 
good accuracy, 189,190 clinical validation studies assessing impact on treatment are 
warranted. 191 
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Mixed venous oxygen saturation describes the oxygen saturation of mixed venous 
blood and can only be obtained using a PAC. This hemodynamic parameter is the only 
one that actually describes the relationship between systemic oxygen supply (DO2) and 
demand (VO2). A decrease in SVO2 indicates an imbalance in these two parameters, either 
through a decrease in DO2 or an increase in VO2. During an increase in VO2, also under 
physiological conditions, O2 extraction and CO increase. A decrease in SVO2 is therefore 
not synonymous with tissue hypoxia, but it indicates the extent to which the oxygen 
reserves are stressed.192 During microcirculatory derangements and shunting of the 
capillaries, such as during distributive shock, SVO2 may be normal, or high, despite local 
tissue hypoxia. Under such circumstances, other means of assessing sufficient global and 
tissue perfusion, such as measurement of CO and lactate values, are needed.  193 
 
 
 
2.6.3 DYNAMIC PRELOAD MEASURES AND CONCEPT OF FLUID 
RESPONSIVENESS 
 
Assessment of preload status in the hemodynamically unstable patient in the ICU is a 
difficult task. The question is will this patient increase cardiac output and thus oxygen 
supply with further fluid resuscitation. Only about 50% of patients with hemodynamic 
failure in the ICU will respond to fluid loading by an increase in CO. 194 Fluid 
responsiveness is the term used to describe the ability to increase CO in reaction to 
volume expansion. In several studies, positive fluid response has been defined as an 
increase of either SV or CO by 15% or more. 195 The gold standard for assessing fluid 
responsiveness has long been “the fluid challenge” accompanied by repeated CO 
monitoring.  196 According to the Frank-Starling curve, there is a curvilinear relationship 
between preload and SV, and hence, CO. An increase in preload will increase CO 
significantly, but only as long as the ventricle operates on the steep part (ascending 
portion) of the curve. If the ventricle is operating on the flat part of the curve, an increase 
in preload will only result in a marginal increase in CO, while simultaneously exposing the 
patient to possible deleterious effects of hypervolemia such as edema formation. 197 There 
is also increasing evidence that greater fluid loads are associated with worse outcome. 198-
202 Static filling pressures have proven unreliable in assessing preload status, having the 
adequacy of coin tossing, and repetitive unnecessary fluid boluses may indeed cause 
harmful overhydration.  37,179 
 
In normal individuals with spontaneous breathing, blood pressure decreases during 
inspiration. Usually, in healthy individuals, it does not decrease by more than 5 mmHg. 
Nevertheless, in certain conditions, such as in constrictive pericarditis, this phenomenon 
is exaggerated, causing greater swings in blood pressure and the complete disappearance 
of the radial pulse during inspiration. This has been termed Kussmaul’s sign, first 
presented by Adolf Kussmaul in 1873.  203 A reversed phenomenon occurs during positive 
pressure ventilation. This has been called reversed pulsus paradoxus, systolic pressure 
variation, and respirator paradox, among others.  204 Morgan and coworkers first reported 
that mechanical ventilation causes cyclic changes in blood flow of the vena cava, 
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pulmonary arteries, and aorta. 205 Later, Rick and Burke described an association between 
volume status and systolic pressure variation in critically ill patients.  204,206 
 
During positive pressure inspiration intrathoracic pressure increases, which 
concomitantly increases the opposing pressure for venous return, thus impeding filling of 
the right atrium and ventricle. This, after a phase lag of a few heartbeats, usually during 
expiration, leads to a decrease in left ventricular preload and stroke volume. The swing 
phenomenon is further augmented by an increase in right ventricular afterload through 
an increase in pulmonary vascular resistance during inspiration and an increase in left 
ventricular preload through squeezing of the pulmonary vascular beds and a decrease in 
left ventricular afterload during inspiration. This results in an increase in stroke volume 
and systolic blood pressure during mechanical inspiration and a decrease of both during 
mechanical expiration.  195 
 
During spontaneous breathing the opposite occurs. Hypovolemia amplifies these 
findings, while hypervolemia diminishes the variation by counteracting the underlying 
mechanisms.195 The decrease in systolic blood pressure during expiration from the 
systolic pressure reference line measured during an end-expiratory pause, ∆Down, has 
been found to accurately reflect volemic conditions and to also be associated with 
responsiveness in both animal 207-209 and clinical studies. 210-212 A multitude of studies have 
assessed the capability of changes in arterial waveform, stroke volume variation (SVV), 
and pulse pressure variation (PPV) during mechanical ventilation to accurately predict 
fluid responsiveness. Michard and coworkers noted that changes in pulse pressure 
reliably predicted fluid responsiveness in patients with acute circulatory failure over 20 
years ago. 213 Since then, different dynamic indices, such as PPV or SVV during positive 
pressure ventilation, have been shown to be superior indicators of fluid responsiveness 
compared with static preload indices, and different monitoring appliances have been 
developed. 214,215 However, because of their dependence on blood pressure or SVV induced 
by respiration, they may be unreliable in clinical practice due to arrhythmias or 
spontaneous breathing efforts.  216,217 
 
Passive leg raising (PLR) is, as the term implies, a maneuver during which the legs of 
the patient are passively lifted. Usually, it is performed in the ICU by tilting the bed. This 
has been described as a means of assessing fluid responsiveness, as it mobilizes about 
200-400 ml of blood from the lower extremities to the venous return, thereby increasing 
preload. If the patient is fluid-responsive, the maneuver will transiently increase SV and 
CO, as assessed by some means of continuous CO monitoring device or echocardiography. 
Unlike the classic fluid challenge, PLR will not increase the total fluid load. The use of 
PLR requires a means of real-time assessment of hemodynamic changes, preferably 
Doppler assessment of aortic flow.218-222 PLR has adequately predicted fluid 
responsiveness during spontaneous breathing and extra-corporeal life support, but 
evidence indicates that it is not reliable during increased intra-abdominal pressure.  223-225 	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2.6.4 ECHOCARDIOGRAPHY FOR HEMODYNAMIC MONITORING 
 
Echocardiography is of great importance in the assessment of cardiogenic shock. The 
evaluation of local or global akinesia or hypokinesia and identification of mechanical 
complications of myocardial infarction are important in setting a diagnosis, as is the 
assessment of valvular function. 226-228 Echocardiography has also become increasingly 
important in the ICU in assessing other patient groups with hemodynamic failure.   
226,229,230 The advantage of echocardiography over catheter-derived parameters lies in its 
ability to visualize the heart and to reveal obvious underlying pathology for hemodynamic 
failure, e.g. cardiac tamponade. 166 Due to improvement of ultrasound appliances and 
image acquisition, transthoracic echocardiography (TTE) instead of transesophageal 
echocardiography (TEE) should be the primary method in the ICU because of its safety 
and lack of invasiveness. 228,230 Evidence exists that echocardiographic methods are 
accurate for assessing fluid responsiveness.  231-234 Respiratory changes in the inferior vena 
cava assessed by TTE have predicted fluid responsiveness in two separate clinical studies 
of septic patients with circulatory shock.  233,234 Using TEE, Feissel and coworkers found 
that the variation of aortic maximum velocity was a good predictor of fluid responsiveness 
in patients with septic shock. 231 Also using TEE, the group of Viellard-Baron assessed the 
collapsibility of the superior vena cava for prediction of fluid responsiveness. 232 A 
collapsibility index of over 36% was associated with an increase in CO to subsequent 
volume expansion. 232 In addition, data from an experimental animal study indicate the 
potential usefulness of variation of the aortic time velocity integral to predict fluid 
responsiveness. 235 Echocardiography may also be used for the assessment of cardiac 
filling pressures in the ICU setting. 236 Moreover, echocardiography is also useful for 
diagnosing systolic and diastolic dysfunction, thus enabling optimal hemodynamic 
support.  160,163,237 However, it must be kept in mind that TTE has been validated against 
thermodilution-derived CO measurements, which currently are considered to be the gold 
standard in a minority of the conducted studies. 238 	  	  
2.6.5 MONITORING OF MICROCIRCULATION 
 
There is evidence that hemodynamic resuscitation targeting certain macrohemodynamic 
target values is not always sufficient to adequately restore tissue oxygenation and prevent 
development of organ dysfunction. 29,239,240 In recent years, the focus has turned to the 
microcirculation and its restoration. As a result, there is growing interest in monitoring 
the microcirculatory function.  170 
 
Mixed venous oxygen saturation describes the relationship between oxygen supply 
and demand, but it cannot recognize a local mismatch, particularly of organs in which the 
perfusion may be compromised before others.170 Lactate, which cumulates during 
hypoxia, may also be used as a marker of tissue hypoxia, but is also not sensitive for local 
changes and is somewhat non-specific. 241-247 The use of the lactate-to-pyruvate ratio for 
assessment of microcirculatory function was described by Weil and Afifi in a clinical study 
over 40 years ago.  241 Tissue carbon dioxide concentrations (tCO2) have also been shown 
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to correlate with derangements in tissue perfusion. Tissue hypercarbia may be assessed 
by sublingual or buccal capnometers, which are not, however, widely used in clinical 
practice today.  49,248 
 
Near-infrared resonance spectroscopy (NIRS), which measures the oxygen saturation 
from the fractions of oxyhemoglobin and deoxyhemoglobin, may be used for assessment 
of tissue oxygen saturation (StO2). The technique of combining measurement of thenar 
StO2 and a brief episode of forearm ischemia shows promise for quantification of 
microvascular dysfunction. 249 Microvideoscopic techniques, such as orthogonal 
polarization spectral imaging (OPS) and sidestream dark field imaging (SDF), visualize 
the microcirculation and enable the clinician to assess the heterogeneity of the capillaries, 
the proportion of perfused versus non-perfused capillaries. These techniques are mainly 
used in research.  170,249 
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2.7. TREATMENT OF HEMODYNAMIC FAILURE 
 
 
Until the end of the 1960s, treatment of shock was symptomatic. The Trendelenburg, or 
the head-down position, was widely used for hemodynamic optimization. Blankets or 
heating devices were used to conserve body heat. In addition, blood pressure was raised 
with drugs. Due to advances in shock research during the 1960s, Weil and Shubin were 
able to propose a novel approach to shock treatment in 1969, the “VIP approach”. 250 The 
focus was now on early and efficient treatment with a systematic approach, allowing 
the physician to gain diagnostic insights while treating the patient. The VIP approach 
consisted of three therapeutic-diagnostic maneuvers: ventilation, infusion, and 
pumping. A postscript, PS, was added to describe the importance of pharmacological 
and surgical treatment, when needed.  250  	  
Despite numerous advances and a myriad of studies in the field, VIP still depicts the 
essence of shock treatment today. In current guidelines, fluid and vasopressor therapies 
are advocated to reach certain hemodynamic targets, primarily a MAP ≥65 mmHg and 
CVP of 8-12 mmHg. Although there has been much debate as to the correct targets and 
the adequacy of CVP as an indicator of fluid status, these targets are still the mainstay of 
current guidelines.  35 	  	  
2.7.1 FLUID TREATMENT 
 
The history of intravenous fluid therapy allegedly began during the European cholera 
epidemic in 1831. The young Irish physician William Brooke O’Shaughnessy proposed 
water and salt repletion as supportive care for cholera patients.  There was little 
progress until Ringer and Schwartz revived the research in intravenous fluid therapy in 
the 1880s, but still intravenous fluid was only given to extremely ill patients. During 
World War II blood transfusions were widely given to wounded soldiers. 251 A new 
enthusiasm for crystalloid infusions began in the 1960s, and the importance of fluid 
repletion in shock became apparent later that decade. 250,251 In the following decades, 
attention was directed to oxygen supply and consumption, targeting supranormal levels 
of oxygen supply, but this regime later turned out to be a disappointment.  29,240,252,253 
The importance of timely, early goal-directed therapy (EGDT) of shock became 
apparent with the study by Rivers in 2001.  25  
 
The key factors in the EGDT treatment algorithm were early recognition of septic 
patents and prompt initiation of treatment, which included fluid resuscitation, packed red 
blood cell transfusions, and inotrope treatment. 25 In 2004, the treatment guidelines of 
septic shock in the “Surviving Sepsis Campaign” emphasized the importance of an acute 
resuscitation bundle with timely fluid resuscitation. 174 Prompt and vigorous fluid 
resuscitation was also highlighted in the two following versions of the sepsis guidelines 
targeting hemodynamic goals of resuscitation.  35,175 
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The initial step in optimization of hemodynamics in circulatory failure is fluid 
resuscitation. 254 Fluid resuscitation in shock aims at restoring intravascular volume, 
hemodynamics, tissue perfusion, and ultimately cellular metabolism to an adequate level, 
primarily by increasing CO.  35,254 Restoration is ideally performed during hemodynamic 
monitoring for assessment of treatment response and should be performed early to avoid 
development of end-organ failure254 The choice of fluid has been the subject of several 
studies.  255-258 Resuscitation with fluids containing albumin was assessed in the SAFE 
study. Patients with septic shock showed a trend of reduction in mortality when 
resuscitated with albumin solution, but there was an increased mortality in patients with 
severe brain injury who were allocated to albumin treatment. 255 Albumin is 
recommended in current treatment guidelines for sepsis in patients needing high 
amounts of crystalloids during resuscitation. 35 Synthetic colloids, such as hydroxyl ethyl 
starches (HES) and gelatine, have been largely used in fluid resuscitation due to their 
alleged superiority in replacing intravascular volume, despite their higher costs and the 
lack of randomized controlled trials showing a clear benefit.  258,259 They have been 
associated with an increase in allergic reactions, derangements in hemostasis, pruritus, 
and kidney injury. 258 Although newer HES solution with lower molecular weights and 
reduced substitution may have less impact on coagulation, 260 shock was reversed with no 
more delay using crystalloids in a prospective study. 261 Furthermore, the volume 
requirements were only marginally lower using HES than crystalloids. 261 During recent 
years an increasing amount of data has indicated that the use of HES is associated with 
serious adverse effects, such as an increase in AKI and greater mortality. 256,257 In a 
Cochrane review of 42 studies, the incidence of AKI and the need for renal replacement 
therapy (RRT) was higher in patients treated with HES. 262,263 The use of HES solutions is 
not currently advocated in the treatment of patients with sepsis. 264 
 
Theoretically, the use of hypertonic saline may have advantages for resuscitation. 
Although some evidence exists of a benefit in certain circumstances, overall the data for 
use in humans are not convincing. Hypertonic saline has been shown to effectively reduce 
elevated intracranial pressure, but this treatment has not improved clinical outcome in 
randomized trials.  258 There is also some evidence of deleterious effects of normal saline 
for fluid treatment. 265 In the trauma setting, evidence also exists for an outcome benefit 
of a restrictive, hypovolemic resuscitation regime prior to surgery to treat sites of blood 
loss.  266 
 
The general consensus is that fluid therapy should be initiated as early as possible. 
However, the optimal amount of fluid to be administered remains obscure. 258 The 
adverse effects of aggressive fluid therapy are well known. 267 In recent years, evolving 
data have raised concern of the deleterious effects on outcome of liberal fluid replacement 
regimens compared with restrictive ones in several critically ill patient groups.  200,201,268-
270 The retrospective studies could not answer the question of whether adverse outcome 
was due to fluid overload or differences in severity of illness.  A prospective study clearly 
showed a benefit of a restricted fluid strategy in terms of ventilator-free days and length 
of stay in the ICU, despite a lack of differences in mortality. 201 These recent advances 
emphasize the importance of prediction of fluid responsiveness in order to avoid excess 
fluid therapy.  198  
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2.7.2 VASOPRESSORS 
 
Vasopressors have been used in the treatment of shock since the early 1940s. 
Interestingly, the different impacts of norepinephrine (and metaraminol) on renal blood 
flow and glomerular filtration in healthy subjects, and in those with vasodilatory or 
hemodynamic shock, were assessed as early as in 1955.  271 The influence of acidosis on 
vascular responsiveness to catecholamines was also elucidated in the late 1950s.  272 
 
The use of vasopressors is recommended in the current guidelines when fluid 
repletion alone cannot restore hemodynamic stability and sufficient perfusion. 
Vasopressor therapy is also frequently required to sustain life and maintain perfusion, 
even though hypovolemia has not yet been completely resolved.  35  
 
The vasopressors used in the ICU are mainly catecholamines, with different profiles as 
to effects on α- receptors and β-receptors, with some also acting on dopamine receptors. 
Vasopressin is a peptide hormone, with entirely different mechanisms of action than the 
catecholamines.  273 Vasopressors mainly induce vasoconstriction of the arterioles, thus 
counteracting excess vasodilation and increasing venous return. Through β-receptor-
mediated mechanisms, they may also exert direct actions on myocardial contractility and 
heart rate.  273 Until recently, no consensus has existed regarding the superiority of any 
particular vasopressor.  However, prospective randomized studies reveal the most 
beneficial profile to be possessed by norepinephrine, a potent α-adrenergic agonist, with 
less potent β-receptor action, in treating patients with hemodynamic failure. 274,275 
Norepinephrine and dopamine, the natural precursor of norepinephrine and epinephrine, 
have until now been considered equal first-line vasopressors for treatment of shock,  175 
although some evidence from a large retrospective study has suggested that dopamine 
was associated with worse outcome.  95,175 Data from earlier studies also indicated that 
norepinephrine was more efficient in achieving targets of blood pressure and plausibly 
had a more beneficial effect on splanchnic circulation.  276,277 However, evidence based on 
several prospective randomized studies of septic shock now shows that dopamine 
treatment is associated with other adverse effects such as arrhythmia and tachycardia. 
274,278,279 In two recent systematic reviews and a meta-analysis, treatment with 
norepinephrine was superior to dopamine also in terms of lower mortality. 278,280 
Consequently, norepinephrine is now considered the primary vasopressor in septic shock.  
35  
 
The renal effects of norepinephrine and particularly dopamine have been the subject 
of much debate. Due to dopaminergic mechanisms, dopamine vasodilates renal and 
mesenteric beds at low doses. Previously, this effect was considered beneficial for 
maintaining renal function.  273,281 However, a large randomized study showed no benefit, 
and subsequently, the use of “renal dopamine” has not been advocated.  281 The effects of 
norepinephrine on renal blood flow appear different between normal subjects and 
patients in shock.  271,282 Although norepinephrine may cause harmful vasoconstriction 
during physiological circumstances, it seems to be beneficial in terms of glomerular 
filtration and creatinine clearance in patients with shock, at least when raising blood 
pressure from levels below the lower range of autoregulation.  44,282 Nevertheless, a higher 
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total catecholamine load has been associated with worse outcome in patients with septic 
shock.  45 
 
Other catecholamines have also been studied in the treatment of shock. 283-286 
Phenylephrine, a synthetic, selective α1-agonist, increases blood pressure through 
vasoconstricton. There is, however, concern that it may decrease cardiac output and 
impair splanchnic blood flow, based on animal and clinical studies. 275,283,286-288 Therefore, 
it is not recommended as a primary vasopressor in shock. The use of epinephrine, an α- 
and β-adrenergic catecholamine, has also been subject to controversy. Epinephrine 
increases cardiac oxygen delivery, but concomitantly it increases myocardial oxygen 
consumption. It has been shown to induce hyperlactatemia and acidosis through direct 
metabolic effects, but this may be difficult to differentiate from changes caused by tissue 
hypoxia.  286 Concerns have been raised regarding impaired splanchnic perfusion.  273,286 
Two large prospective randomized studies comparing epinephrine to norepinephrine 
(with addition of dobutamine) found no differences in mortality. 273,285,286,289 In the 
epinephrine group, lactate levels were higher and acidosis was more common, but the 
incidence of serious adverse effects in terms of arrhythmias was similar. 285,289 
Epinephrine is recommended as a second-line vasopressor in the current guidelines.  35 
 
Vasopressin is normally synthesized in the hypothalamus, is stored in the pituitary 
gland, and acts in a completely different manner to catecholamines. Under normal 
physiological conditions, vasopressin has little effect on blood pressure. It is released in 
response to hypovolemia and increases with plasma osmolality. It causes vasoconstriction 
via V1 receptors and increases responsiveness to catecholamines.  273,290 Vasopressin levels 
increase in hemorrhagic shock, but the response seems abnormally low in septic shock,291 
possibly due to depletion of pituitary stores.  292 Its use has been associated with ischemic 
skin and tongue lesions, and concern has been raised as to its possible deleterious effects 
on splanchnic circulation.  286  
 
Two small randomized trials comparing vasopressin with norepinephrine showed a 
decrease in catecholamine requirements in the vasopressin group. 293,294 A large 
randomized trial revealed no difference in outcome between patients with septic shock 
receiving vasopressin and those receiving norepinephrine, but patients who were less 
severely ill seemed to benefit from vasopressin therapy. 295 A post hoc analysis of the same 
trial showed that patients at risk of AKI had a lower incidence of AKI progression and 
lower mortality rates when treated with vasopressin.  296 In another post hoc study of the 
same trial, the combination of vasopressin and corticosteroids was associated with a 
decrease in incidence of organ dysfunction and mortality. 297 Two recent systematic 
reviews and meta-analyses assessed vasopressin as treatment for vasodilatory shock. The 
conclusions differed somewhat, but neither review found vasopressin to be associated 
with worse outcome than catecholamines. 298,299 The use of vasopressin is currently 
advocated only in combination with norepinephrine at low doses 35 as repletion therapy, 
although some data show good response also at higher doses.  300 
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2.7.3 INOTROPES 
 
The use of inotropes is indicated in shock when fluid therapy and vasopressor therapy are 
inadequate for restoring tissue perfusion and oxygen supply. They are administered to 
increase force and rate of myocardial contractility, and thus, CO and oxygen delivery.  301  
 
In the 1960s, the focus shifted to the balance between oxygen delivery (DO2) and 
consumption (VO2), as measurement of CO and oxygen content in blood became possible 
at bedside. The concept of pathologic oxygen supply dependence, a linear relationship 
between DO2 and VO2, was postulated. The rationale was that an increase in DO2 would 
be beneficial for patients in shock, as oxygen debt and energy deficit had been found to 
be associated with poor outcome in clinical studies.  302 Targeting supra-normal levels of 
DO2 as part of “supra-normal” resuscitation by using inotropes, fluids, and blood 
transfusions seemed beneficial in early studies of high-risk surgical patients.  252,303,304 
The results from two prospective randomized studies showed either no improvement 240 
or increases in mortality, 29 consistent with several other studies, 35,302 and supra-normal 
resuscitation has not been advocated since. 
 
The use of inotropes as part of treatment of shock today relies on scant evidence of 
their beneficial effects. The study by Rivers and coworkers in 2001 showed a marked 
outcome benefit for the treatment arm in which dobutamine was included for achieving 
targets of ScVO2. 305 Similar results have been shown by Jones and coworkers in 2010. 306 
Several studies are currently being conducted to assess the benefit of the treatment 
algorithm presented by Rivers relative to current clinical practices. 307 In patients with 
chronic cardiac failure, inotropes, particularly catecholamines, have been clearly 
associated with adverse effects and worse outcomes.  26-28 
 
In septic shock, CO is often increased. Nevertheless, in a substantial proportion of 
patients, septic cardiomyopathy is present, evidenced by impairment of systolic or 
diastolic function, or both, without structural changes.  308,309 In these patients, based on 
measured or suspected low CO, and high filling pressures or adequate fluid status, in 
addition to adequate blood pressure level, inotropic treatment is currently recommended, 
guided by trends in clinical data of hypoperfusion. 35,308 Dobutamine, a synthetic 
catecholamine available as a racemic mixture, with mixed β-receptor and modest α-
receptor effects, is the primary inotrope recommended for these purposes, despite little 
evidence of an outcome benefit. 35,301 Dobutamine has also been used to treat cardiogenic 
shock, and as it increases myocardial oxygen demand, it is used as a stressor in cardiac 
assessment. 301 However, in a recent meta-analysis it was associated with worse outcome 
in terms of mortality in severe heart failure.  310 It causes an increase in cardiac output, 
stroke volume, and heart rate, but it may cause malignant ventricular arrhythmias at any 
dose. 311,312 There is also evidence of improvement of microcirculation with the use of 
dobutamine, but as yet, no clear evidence has emerged of less end-organ failure.  302 
 
During the last twenty years there has been increasing interest in levosimendan, a 
calcium-sensitizing inodilator. It has a dual mechanism of action, including both calcium 
sensitization, which enhances contractility, and opening of ATP-dependent potassium 
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channels, which induces vasodilatation. 312 Some results have indicated that levosimendan 
may improve survival in surgical and cardiologic settings. 313 However, evidence of 
beneficial effects in septic shock is scarce, although some prospective studies have shown 
promising results.  314-316 
 
Currently, neither levosimendan, milrinone, nor other phosphodiesterase inhibitors 
are recommended in the treatment of septic shock. 35,317 A small study assessing the 
potential role of milrinone and enteral β-blockers in shock,  35,318 demonstrated that such a 
treatment regime is feasible and also potentially beneficial in terms of improvement of 
hemodynamic parameters.  318,319 	  	  
2.7.4 ADJUVANT THERAPIES 
 
Treatment of shock does not merely consist of administration of fluids and vasoactive 
substances. The underlying cause needs to be addressed promptly and accurately. In 
cardiogenic shock, early revascularization and mechanical support by intra-aortic balloon 
pump (IABP) counterpulsation are currently recommended, in addition to fluid and 
vasoactive therapy, 67 although recent data suggest that counterpulsation is associated 
with neither short-term nor long-term survival benefit.  67,320,321 In septic shock, the early 
administration of effective antimicrobial treatment has proven beneficial in terms of 
outcome in several studies.  35,322 In addition, early and adequate source control of the 
infection is also advocated, preferably within 12 hours of diagnosis. 35 For patients 
suffering from hemorrhagic shock, source control, i.e. stopping the source of bleeding, is 
essential for obvious reasons in addition to restoration of blood volume.  323 
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2.8 OUTCOME IN HEMODYNAMIC FAILURE OR CIRCULATORY 
SHOCK 
 
 
A Finnish study, conducted in the late 1990s, assessed the association between resolution 
of circulatory failure and outcome.  Altogether 83 patients with circulatory failure were 
evaluated. The overall hospital mortality was 39.8% and the ICU mortality 33.7%. Sepsis 
was diagnosed in 20% of the patients. 239 In a large European study conducted in 24 
countries in 2002, the mortality of all patients with shock was 38%, while it was 47.4% for 
patients with septic shock. The mortality for patients with hemodynamic failure without 
sepsis was 34%. The mortality for patients with sepsis and any degree of hemodynamic 
failure was significantly higher, 42%. 95,96  	  
In the Finnsepsis study conducted in 24 Finnish ICUs in 2004-2005, the overall ICU, 
in-hospital, and 1-year mortalities were 16%, 28%, and 41%, respectively. The mortality 
for patients with cardiovascular failure (SOFA subscore ≥ 3, without other organ 
dysfunctions) was 33%. The mortality rose to 69% in patients with SOFA subscores of at 
least 3 points in all organ groups. 10 The mortality rates rise with advancing age. In a 
recent substudy of the European SOAP II study, the mortalities for patients with 
hemodynamic failure aged under 75 years, 75-84 years, and over 85 years were assessed. 
The 6-month mortality for these three age groups was 59%, 79%, and 92%, respectively. 
The cause of death in the age groups was shock in 20%, 24%, and 26%, respectively. 324 
 
Mortality rates for cardiac shock previously ranged from 50% to 80%. 105, but have 
now declined due to early intervention therapies. 66 In an American study, comprising 
data from 775 US hospitals during 1995-2004, the hospital mortality in cardiogenic shock 
at the beginning of the study was 60%, but had decreased to 48% by the year 2004. 67 In 
Finland, the current hospital mortality due to cardiogenic shock is 46-48%. 104 
 
According to previous studies, anaphylactic shock leads to lethal outcome in 3-10% of 
cases. 325 The mortality rates in hemorrhagic shock vary widely based on the underlying 
trauma mechanisms, but in recent studies mortality rates ranging from 15% to 40% have 
been reported.323 	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3. AIMS OF THE STUDY 
 	  
The objective of this study was to assess the relevance of early hemodynamics and 
hemodynamic treatment for outcome and development of end-organ injury in patients 
with severe sepsis, septic shock, and severe acute pancreatitis. In addition, methods for 
evaluating fluid responsiveness at bedside in patients with septic shock were sought. 
 
 
Specific aims of the study were as follows: 	  	  
1. To assess the association of inotrope treatment and early hemodynamic 
variables with outcome in patients with septic shock, with a subgroup 
analysis of patients monitored by a pulmonary artery catheter. 
 
 
2. To assess the association of early hemodynamic variables and vasoactive 
treatment with outcome in patients with severe acute pancreatitis, with a 
subgroup analysis of patients with circulatory shock. 
 
 
3. To evaluate whether elevation of PEEP from 10 to 20 cm H2O induces 
hemodynamic changes in mean arterial pressure, systolic arterial pressure, 
or pulse pressure or changes in parameters derived by transesophageal 
echocardiography that would predict fluid responsiveness in patients with 
septic shock. 
 
 
4. To assess the association of early hemodynamic variables, with special 
reference to time-adjusted mean arterial pressure, and vasoactive 
treatment with the development of acute kidney injury during the five first 
days in the intensive care unit in patients with severe sepsis. 
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4. PATIENTS AND METHODS 
 
 
 
4.1 PATIENTS 
 
 
We included 1022 patients in Studies I to IV. Studies I to III were conducted at Helsinki 
University Central Hospital, and Study IV was a Finnish multicenter study conducted in 
17 Finnish ICUs. The flowchart of inclusion of patients into the studies is presented in 
Figure 6. The demographic data of the patients of Studies I to IV are shown in Table 1. 
The Ethics Committee of Helsinki University Central Hospital approved all study 
protocols. In Studies III and IV, written informed consent was given by the patient or a 
proxy. Written consent was waived by the Ethics Committee for Studies I and II. 	  
Study I was a retrospective cohort study conducted in two ICUs (9-bed mixed and 10-
bed surgical ICU) at Helsinki University Central Hospital. All 3496 consecutive patients 
in the ICUs during the period from 1.1.2005 to 31.12.2008 were considered eligible for the 
study. We identified 526 patients with a diagnosis compatible with sepsis registered on 
admission and later confirmed on discharge (pneumonia, urosepsis, intra-abdominal 
sepsis, CNS infection, or sepsis). The 420 patients included in the study had a diagnosis 
compatible with sepsis and need for vasopressor support during the first 24 hours in the 
ICU. A subgroup analysis was also performed on the 252 patients monitored by a 
pulmonary artery catheter. 
 
Study II was a retrospective cohort study conducted in the same two ICUs at Helsinki 
University Central Hospital. All 3496 consecutive patients treated in the ICUs between 
1.1.2005 and 31.12.2008 were assessed for eligibility. The 159 patients of the study were 
retrospectively identified based on the International Classification of Diseases (ICD-10) 
diagnoses “acute pancreatitis” (ICD-10: K85) or “ acute alcohol pancreatitis” (ICD-10: 
K86.00). In addition, a subgroup of 73 patients with circulatory shock, defined as need of 
hemodynamic support by use of norepinephrine at a dose exceeding 0.1 µg/kg/min for 
one hour, was identified. 
 
Study III was a prospective study conducted in one ICU at Helsinki University Central 
Hospital during 2006-2012. All patients with septic shock defined by the APCCP/SCCM 
Consensus Conference criteria, an inserted pulmonary artery catheter, age over 18 years, 
sinus rhythm, mechanical ventilation and sedation, pulmonary artery occlusion pressure 
(PAOP) ≤ 18 mmHg, and use of norepinephrine at a dose of at least 0.1 µg /kg/min for 
hemodynamic support were considered eligible for the study. The 20 patients of the study 
fulfilled the inclusion criteria and met none of the exclusion criteria (contraindication to 
elevation of PEEP or performing TEE, heart valve insufficiency, or stenosis). 
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Study IV was a predefined substudy of the prospective observational FINNAKI study 
that was conducted in 17 Finnish ICUs from 1.9.2011 to 1.2.2012. All 918 patients of the 
FINNAKI study filling the APCCP/SCCM Consensus Conference criteria of severe sepsis 
were assessed for eligibility. Patients from 4 ICUs were excluded due to incomplete 
hemodynamic data. Moreover, patients who fulfilled the criteria of severe sepsis later 
than 24 hours, or fulfilled the endpoint (development or progression of AKI) within 12 
hours of admission to the ICU, or died within 5 days of admission to the ICU were 
excluded. The final study population consisted of 423 patients with severe sepsis from 13 
Finnish ICUs. 	  	  	  
 
 
 
Table 1. Demographic data of Studies I to IV. 	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4.2 STUDY DESIGNS AND PROTOCOLS 
 
 
Study I was a retrospective study in which we assessed the effect of use of inotrope 
treatment on 90-day mortality and examined factors associated with the initiation of 
inotrope treatment in patients with septic shock. Patient data were retrospectively 
collected from the clinical data management system (PICIS, Wakefield, MA, USA, and 
Dräger Medical, Lübeck, Germany) and from the Finnish Intensive Care Consortium 
database (Tieto Oy, Helsinki, Finland). Mortality data were obtained from the Finnish 
Intensive Care Consortium database and from the Population Register Center in Helsinki, 
Finland. Demographic and continuously measured hemodynamic data as well as data of 
vasopressor and inotrope use and other medications for hemodynamic support were 
collected and statistically analyzed. We assessed the association of demographic data, 
disease severity scores (APACHE II and SOFA for day I), hemodynamic variables, 
vasopressor treatment, blood lactate levels, and indicators of renal function (serum 
creatinine and urine output) with the initiation of inotrope treatment.  Most importantly, 
the association between inotrope treatment during the first 24 hours in the ICU and 
outcome was assessed. The primary endpoint was 90-day mortality, but hospital 
mortality, ICU and hospital lengths of stay, and 1-year mortality were also assessed. A 
subgroup of patients monitored by using a pulmonary artery catheter was evaluated for 
PAC-derived hemodynamic parameters associated with use of inotropes and outcome. In 
this group of patients, the ability to respond to inotrope treatment by an increase in SV 
and CI was assessed. The changes in hemodynamic parameters induced by inotrope 
treatment and their association with outcome were also evaluated. To reduce the selection 
bias of more severely ill patients receiving inotropes with a higher propensity, adjustment 
with propensity scoring based on observed variables was performed in both the general 
study population and the subgroup monitored by PAC. Due to the retrospective design of 
the study, patients were treated according to current international and local guidelines at 
the discretion of the attending physician. 	  
Study II was a retrospective cohort study in which the association of early 
hemodynamic variables (first 24 hours in the ICU) with outcome was assessed in critically 
ill patients with severe acute pancreatitis. Demographic data, disease severity scores, 
continuously measured hemodynamic variables, data of renal function and data of 
vasopressor and inotrope therapy were collected as described for Study I. The association 
of hemodynamic variables and hemodynamic support of the general study population and 
those of the subgroup with circulatory shock with 90-day mortality, which was the 
primary endpoint, was assessed. The associations of hemodynamic variables with early 
mortality (within 14 days of ICU admission) and ICU and hospital lengths of stay were 
also assessed.  
 
In Study III, an interventional prospective study, the predictive values of changes in 
hemodynamic parameters during elevation of PEEP from 10 to 20 cm H2O were 
evaluated. The study algorithm is shown in Figure 7. Upon inclusion of the patient into 
the study, PEEP was set at 10 cm H2O. At PEEP 10 cm H2O, baseline catheter-derived 
measurements and TEE were performed. PEEP was then temporarily elevated to 20 cm 
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H2O, during which measurements and TEE were performed again during an end-
expiratory pause. PEEP was then returned to baseline. A volume expansion with plasma 
expander was then conducted, after which the measurements and TEE were re-performed 
for assessment of response to fluid. All patients were mechanically ventilated, sedated, 
and paralyzed during the study. The changes in catheter-derived hemodynamic values 
and in left ventricular end-diastolic area (LVEDA) and aortic velocity time integral 
(VTIAo) assessed by TEE were statistically evaluated for their ability to predict fluid 
responsiveness. The changes in respiratory parameters, blood gas analysis, and DO2 
induced by elevation of PEEP and volume expansion were also assessed.  
 
 
 
	  Figure	  7.	  	  Study	  algorithm	  for	  Study	  III	  	  
Study IV was a predefined prospective observational substudy of the multicenter 
FINNAKI study.  Its aim was to evaluate the association of early hemodynamics with 
development and progression of AKI during the first five days in the ICU. Special 
emphasis was put on MAP and vasoactive treatment during the first 24 hours in the ICU. 
Routine data (demographics, diagnoses, disease severity scores, outcome measures) were 
collected from the Finnish Intensive Care Consortium database. A standardized case 
report form (CRF) for registration of data on chronic and present health information, risk 
factors for AKI, infections and antimicrobial treatment, organ dysfunction, fluid balance, 
and information on renal replacement therapy (RRT) was filled at admission and daily 
during days one to five in the ICU, and at ICU and hospital discharge. KDIGO criteria326 
for AKI were assessed continuously based on urine output and measured creatinine 
values. The last serum creatinine (SCr) value from the preceding year, excluding the week 
before admission, was used as the baseline. If no baseline values were available, the 
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Modification in Diet in Renal Disease (MDRD) equation was used. The time-adjusted 
MAP was calculated based on each median value during the first 24 hours or until 
endpoint was reached and assessed for an association with development of AKI, as shown 
in Figure 8. The areas and aggregate times below MAP threshold values from 55 to 85 
mmHg were calculated and were also assessed for an association with development of 
AKI. Moreover, the associations between vasoactive treatment and factors previously 
known to be associated with AKI, such as comorbidities, fluid balance, fluid therapy, and 
radio-contrast dye, were assessed. 
 
 
 
 
 
 
	  
 
Figure 8. MAP during the first 24 hours for a patient with severe sepsis. The reference line 
is set at 65 mmHg and the arrows indicate (significant) areas below this line 
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4.3 CLINICAL DATA 
 
 
For Studies I, II, and III, intensive care data were retrieved from the Finnish Intensive 
Care Consortium database (Intensium ®, Tieto Oy, Helsinki, Finland), which collects 
data from Finnish ICUs for benchmarking purposes. These data comprise information on 
admission and discharge from ICU and hospital, outcome measures, severity scoring 
[Acute Physiology and Chronic Health evaluation (APACHE II), 327 Sequential Organ 
Failure Assessment score (SOFA), 328 and Simplified Acute Physiology Score (SAPS II) 329], 
diagnosis according to the International Classification of Diseases (ICD-10) classification, 
and basic demographic data such as age and gender. Patients were included into Studies I 
and II based on ICD-10 and APACHE III diagnoses. In these studies, data from the 
Finnish Intensive Care Consortium database were combined with data from the clinical 
data management system (PICIS, Wakefield, MA, USA, and Dräger Medical, Lübeck, 
Germany). Clinical data included continuously measured hemodynamic data and 
information on administration of vasopressors and inotropes and corticosteroid 
treatment. Continuous hemodynamic data (MAP, HR, SVO2, mean pulmonary artery 
pressure (MPAP)) were collected as 5-minute median values. These values were manually 
validated and further filtered to 1-hour median values. Central venous pressure, CI, SV, 
and PAOP were registered every 1 to 6 hours upon measurement. Obvious outliers were 
manually removed from all hemodynamic measurements.  Clinical data also included 
hourly urine output and routine blood sample parameters such as blood lactate and 
serum creatinine. Patients were identified based on individual admission numbers, and 
social security numbers were used for identification and retrieval of outcome data from 
the Population Register Center (Helsinki, Finland). For Study I, admission and discharge 
data from the emergency department clinical data system (Centricity, Clinisoft, GE, 
Fairfield, CT, USA) were collected. For Study II, additional data on surgical treatment was 
collected from the Operation Room Clinical Database (PICIS, Wakefield, MA, USA).  In 
Study III, clinical and demographic data were collected prospectively onto a standardized 
CRF, as were data from hemodynamic measurements and blood samples. The results 
from the TEE were recorded onto the hard disk of ultrasound devices (Vivid I, GE, 
Fairfield, CT, USA), from where data were later retrieved for analyses. 
 
In Study IV, data from the Finnish Intensive Care Consortium database (Intensium ®, 
Tieto Oy, Helsinki, Finland) were combined with prospectively collected data on the 
standardized CRF of the FINNAKI study. In addition, data on MAP and other 
hemodynamic variables, such as CVP, CO, and intra-abdominal pressure (IAP), were 
prospectively collected into the database. The CRF was used for daily registration of data 
on chronic and present health information, risk factors for AKI, sepsis, infections and 
antimicrobial treatment, organ dysfunction, fluid balance, and information on RRT. The 
CRF was first filled on admission, then daily through days 1-5, on discharge from the ICU, 
and finally on discharge from the hospital. Mean arterial pressure was prospectively 
collected in the local database as 2- or 5-minute medians, these values were then 
manually validated for the first 24 hours for eradication of erroneous values before 
conversion into 10-minute medians for analysis. 
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4.4 HEMODYNAMIC MEASUREMENTS 	  
In Studies I, II, III, and IV, invasive measurement of blood pressure was performed 
continuously on all patients, generally by use of a radial arterial catheter as part of routine 
patient care. In some instances, for technical reasons, other anatomic sites for the 
catheter, such as the femoral artery, were preferred. In Studies I and II, CVP was 
monitored by either a central venous catheter or a pulmonary artery catheter. In Study I, 
252 patients (60%) had a pulmonary artery catheter and 156 patients (37%) had some 
other means (central venous catheter) for measurement of central venous pressure; 22 
patients (5.2%) had neither type of catheter inserted within 24 hours of ICU admission. In 
Study II, 64 patients (40%) had a PAC, 155 patients (97%) had another means of CVP 
measurement (central venous catheter), and only 4 patients had neither catheter type 
inserted within 24 hours of admission.  In Study III, all patients had a PAC inserted, as 
this was one of the inclusion criteria of the study. In Studies I and II, CI, SV, CO, PAOP, 
SVO2, and MPAP were all measured by use of a PAC, as other means of performing these 
measurements were not available in the ICUs at the time of the study. In all studies, SVO2 
was measured continuously using a fiberoptic catheter by reflection spectrophotometry. 
In Studies I, II, and III, CO measurements were generally performed by using the 
thermodilution method, ideally by use of 10 ml of ice-cold fluid (+0 - +6 degrees 
centigrade). The mean of three consecutive measurements was generally registered. Heart 
rate was recorded from the continuous EKG registration or alternatively from the arterial 
pressure wave registration. In Study III, the researchers performed thermodilution 
measurements of CO and measurement of PAOP as part of the study protocol during an 
end-expiratory pause.  
 
 
 
4.5 TRANSESOPHAGEAL ULTRASOUND 	  
Transesophageal ultrasound examinations were performed as part of the study protocol 
in Study III. Ultrasound devices with esophageal probes (Vivid I, GE, Fairfield, CT, USA) 
were used.Prior to the first ultrasound examinations at baseline, the adequacy of sedation 
was confirmed, after which the patients were paralyzed by administration of rocuronium 
(0.5 mg / kg) intravenously, and the probe was placed in the esophagus. Transesophageal 
ultrasound, during which left ventricular end-diastolic area and aortic velocity time 
integral (LVEDA and VTIAo) were registered, was performed at baseline (PEEP set at 10 
cm H2O), during elevation of PEEP to 20 cm H2O, and after volume expansion. LVEDA 
and VTIAo were registered and recorded from the transgastric view. LVEDA was measured 
by planimetry from the leading edge of the left ventricular endocardial border, and VTIAo 
was measured by pulse-wave Doppler at the level of the aortic valve. Before commencing 
the study, TTE and TEE were performed to ensure the absence of heart valve pathologies.   	  	  
 
	  62	  
4.6 BLOOD SAMPLES 
 
 
For Studies I, II, and IV, routine blood samples were drawn during normal clinical 
practice and follow-up. Routine laboratory tests comprised blood gas analyses, including 
lactate measurement, SCr, urea concentration, bilirubin concentration, hemoglobin and 
hematocrit, leukocyte and platelet count blood samples for daily assessment of disease 
and organ failure scores. In Study III, blood gas samples were drawn according to the 
study algorithm at baseline and after the volume expansion. 
A laboratory sample protocol was also used for Study IV, but these samples were not used 
in this substudy. 	  	  
4.7 INTERVENTIONS 	  
In Study III, TEE was performed as described in Section 4.5. Moreover, a fluid challenge 
was conducted according to the protocol outlined in Figure 7. The fluid challenge 
consisted of 6 ml/kg plasma expander (Gelofusine, B.Braun Medical, Melsungen, 
Germany) and was given in 30 minutes. Moreover, blood samples were drawn at baseline 
and at the end of the study. Patients in all studies were otherwise managed according to 
local and international guidelines, at the discretion of the attending physicians. 
 	  	  
4.8. DISEASE SEVERITY SCORES AND END-ORGAN FAILURE 	  
In Studies I to IV, disease severity and organ failure scoring were part of normal clinical 
practice and follow-up. These were routinely registered in the Finnish Intensive Care 
Consortium database (Intensium ®, Tieto Oy, Helsinki, Finland), from where they were 
retrieved for the studies. Assessment of organ failures was performed daily in all ICUs 
using the SOFA score.328 The severity of disease at baseline was also assessed using 
APACHE II 327 and SAPS II329 scores after 24 hours in the ICU. 	  
In Study IV, AKI was defined according to the Kidney Disease: Improving Global 
Outcomes (KDIGO) criteria.326 We defined and staged AKI according to changes in serum 
creatinine (SCr) and urine output. The last SCr value from the previous year (excluding 
the week before the ICU admission) was used as the baseline SCr, and for those without a 
baseline value (n=292) we estimated it by using the Modification in Diet in Renal Disease 
(MDRD) equation], assuming a glomerular filtration rate of 75 ml/min/1.73 m2. The 
endpoint in Study IV was defined as new onset or progression of AKI (KDIGO stages I, II, 
or III or initiation of RRT) during days 1 to 5 in the ICU. 
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4.9 GENERAL POLICY IN THE MANAGEMENT OF PATIENTS 
IN THE INTENSIVE CARE UNIT 	  
In Studies I to IV, patients were managed in the ICU according to current international 
and local guidelines,330 at the discretion of the attending physician. Vasopressor 
treatment (mainly norepinephrine) was advocated when fluid treatment alone was 
inadequate to restore targets of MAP, generally a level of at least 65 mmHg. Inotropes 
were recommended when cardiac output or tissue perfusion achieved by fluid 
resuscitation and vasopressor treatment was insufficient, as defined by low CI, low SVO2 
(below 65%), or such clinical signs as cool mottled skin. Insufficient perfusion could also 
be suspected based on high lactate values and low urine output, which did not respond to 
volume expansion. The use of a PAC was recommended in the ICUs when the need for 
vasopressor support (norepinephrine) exceeded 0.1 µg/kg/min in Studies I and II. The 
management of patients with SAP in Study II followed widely accepted international  
331,332 as well as local guidelines. Fluid treatment of these patients also followed current 
guidelines of treatment of sepsis, septic shock, and pancreatitis.  330,332,333 In Study II, 
prophylactic antibiotic therapy was initiated according to local guidelines. Surgical 
treatment was performed early only in cases of abdominal compartment syndrome, when 
conservative means of treatment were futile. Pancreatectomy or pancreatic necrosectomy 
was performed preferentially no earlier than at 3 weeks of illness. Endoscopic retrograde 
cholangiopancreatography was performed if required.  
 
 
 
4.10 OUTCOME MEASURES 
 
The ICU, hospital, and 90-mortality data for Studies I, II, and IV were acquired from the 
Finnish Intensive Care Consortium database and the Population Register Center in 
Helsinki, Finland. Long-term mortality data for Study I was acquired from the Population 
Register Center, Helsinki, Finland. In Study IV, new onset or progression of AKI was the 
primary endpoint (see Section 4.8). 
 	  
4.11 STATISTICAL METHODS 
 
 
STATISTICAL ANALYSES 
The statistical analyses in Studies I and II were performed using SPSS 16.0 and 17.0 
software (SPSS Inc., Chicago, IL, USA).  In Studies III and IV, statistical analyses were 
performed using IBM SPSS Statistics 19.0 and 20.0 software (IBM, Armonk, NY, USA). 
For analysis and calculations of the MAP data of Study IV, NCSS 8 software (Kaysville, 
UT, USA) was used. 
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PRESENTATION OF DATA 
In Studies I to IV, data are presented as absolute numbers and percentages, as median 
values with interquartile ranges (IQR, 25th and 75th percentiles), or as means and standard 
deviations (SD). 	  
STATISTICAL SIGNIFICANCE 
In all studies (I-IV), p<0.05 was considered significant.  
 
 
MANN-WHITNEY U-TEST 
This test was used for comparison of continuous variables between independent groups. 
It was used for hemodynamic, laboratory, and demographic data in Studies I to IV for 
independent groups such as inotrope receivers and non-receivers, survivors and non-
survivors, fluid responders and non-responders, and patients with AKI or without AKI. 
 
PEARSON’S CHI-SQUARE OR FISHER’S EXACT TEST 
These tests were used as appropriate for the comparison of categorical data in Studies I to 
IV. Generally, Fisher’s exact test was used when the number of cases in a sample was less 
than five. 
 
 
KAPLAN-MEIER SURVIVAL CURVES 
Kaplan-Meier survival curves were constructed for 90-day mortality differences between 
inotrope receivers and non-receivers in Study I. 
 
 
MULTIVARIATE LOGISTIC REGRESSION ANALYSIS 
This analysis was used to test the independent effect of variables on outcome. 
 
 
PROPENSITY SCORING 
Propensity scoring was used to reduce selection bias and the influence of confounders in 
Study I. It was calculated based on variables found to be associated with initiation of 
inotrope treatment; outcome measures were not included in the calculation. The 
propensity score for inotrope treatment achieved by multivariable logistic regression was 
then added to the final regression analyses as a covariate.  
 
 
RECEIVER OPERATING CHARACTERISTIC (ROC) CURVE 
ROC analysis, with the calculation of areas under the curve (AUC), was used in Study III 
to evaluate the prognostic value of changes in hemodynamic variables for prediction of 
fluid responsiveness. The best cut-off values were identified using the Youden Index 
method (sensitivity +specificity -1).  334,335 The best cut-off value for clinical purposes was 
identified in Study III as the value at which specificity and negative predictive value were 
highest (100%). 
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In Study IV, ROC analysis was used to evaluate the prognostic value of time-adjusted 
MAP and highest norepinephrine doses in the development and progression of AKI. As in 
Study III, the best cut-off values were identified as the values of highest Youden Index. 
 
 
AREAS UNDER THE ROC CURVE (AUC) 
AUCs were used to determine the accuracy of hemodynamic variables for prediction of 
fluid responsiveness in Study III and the predictive value of time-adjusted MAP and 
highest doses of norepinephrine in development and progression of AKI in Study IV. The 
AUC was calculated with 95% confidence intervals. 
 
 
AREA UNDER CURVE (TRAPEZOIDAL RULE) 
For the calculation of time-adjusted MAP in Study IV, the AUC of 10-minute median MAP 
values on the Y-axis and time as minutes on the X-axis was computed by the trapezoidal 
rule using NCSS 8 software. The time-adjusted MAP was calculated as the AUC divided by 
the aggregate time of MAP follow-up until reaching an endpoint or up to 24 hours. In 
Study IV, the area of MAP x time (minutes) below MAP thresholds (55-85 mmHg) and 
the aggregate time spent below these thresholds were also calculated 
 
 
SENSITIVITY, SPECIFICITY, AND POSITIVE AND NEGATIVE PREDICTIVE 
VALUES 	  
  CONDITION  (Fluid response) 
 Positive                                   Negative 
(Responder)                          (Non-responder) 
 
 
 
TEST  
OUTCOME 
(∆MAP) 
 
Positive 
 
Negative 
 
A=true POSITIVE                 C=false POSITIVE 
 
B=false NEGATIVE              D=true NEGATIVE 
 
   A+C 
 
   B+D 
 
   
          A+B                                            C+D 
 
 
 
Sensitivity, specificity, positive predictive value, and negative predictive value were used 
in Study III and were calculated as follows: 
 
Sensitivity = true positives/ true positives + false negatives = A / (A+B) 
Specificity = true negatives/ (true negatives + false positives) = D/ (C+D) 
Positive predictive value = true positives / (true positives + false positives)= A/ (A+C) 
Negative predictive value = true negatives / (true negatives + false negatives)= D/ B+D) 
  
	  66	  
5. ETHICAL ASPECTS 
 
 
The Ethics Committee of Helsinki University Central Hospital approved all study 
protocols (I-IV). Due to the retrospective design and lack of intervention in Studies I and 
II, informed consent was waived.  
 
Informed consent was obtained from all subjects or next of kin in Study III before 
inclusion in the study. In Study IV, written consent was obtained from all subjects or next 
of kin with a deferred consent policy. 
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6. RESULTS 	  	  
6.1 FACTORS ASSOCIATED WITH INOTROPE TREATMENT 
AND THE ASSOCIATION BETWEEN TREATMENT AND 
OUTCOME IN SEPTIC SHOCK (I) 
 
 
The results showed that inotropes were used rather frequently in patients with septic 
shock in the two ICUs included in the study. Of the 420 patients, 186 (44.3%) received 
inotrope treatment. Patients who were treated with inotropes were generally more 
severely ill, as defined by higher APACHE II scores [24.0 (18.0-29.0) vs. 18.0 (14.0-
23.0)], higher SAPS II scores [45.5 (37.0 - 58.0) vs. 38.0 (29.8-46.0)], and higher SOFA 
score for day 1 [10.0 (8.0-13.0) vs. 8.0 (6.0-10.0)] (p<0.001 for all). The patients who 
received inotropes had higher heart rate, lower MAP, and higher CVP during the first 24 
hours in ICU (p<0.001 for all). These patients also received higher doses of 
norepinephrine and vasopressin, and they more often received sepsis hydrocortisone, all 
indicating a more severe degree of hemodynamic compromise. In addition, the lactate 
levels in inotrope receivers were significantly higher than in non-receivers [4.1 (2.2-6.7) 
mmol/l vs. 2.1 (1.5-3.3) mmol/l, p<0.001]. Higher CVP, higher dose of norepinephrine, 
and higher lactate values were independently associated with inotrope treatment.  Of all 
inotropic substances, dobutamine was used most frequently (90.3% of all inotrope 
administrations). In 147 patients (79%), a single inotrope was used. The mortality of 
patients receiving at least two different inotropes was significantly higher than that of 
those receiving only one (64.1% vs. 36.7%).  	  
When analyzing factors associated with outcome, the results of the multivariable 
regression analysis revealed that use of inotrope treatment [OR 2.29 (1.33-3.94)], higher 
APACHE II score, and advanced age were independently associated with 90-day 
mortality. In a second regression model, in which inotropic substances were analyzed 
separately, dobutamine [OR 2.34 (1.36-4.02)] was associated with 90-day mortality. The 
results remained unchanged when adjusted for propensity to receive inotropes. The 
hospital and 90-day mortalities were significantly higher for inotrope receivers than for 
non-receivers (33.9% vs. 17.1%, p<0.001 and 42.5% vs. 23.9% p<0.001 respectively). 
 
In the subgroup of 252 patients monitored by a PAC, an even higher proportion 
received inotrope treatment (160/252, 63.5%). In this subgroup of patients, a higher 
lactate level and lower SVO2 and CI values were independently associated with inotrope 
treatment. Also in this subgroup, ICU, hospital, and 90-day mortalities were significantly 
higher among inotrope receivers than among non-receivers (28.1% vs. 14.1%, 33.8% vs. 
18.5%, and 41.9% vs. 19.6% respectively) (p<0.02 for all). 
 
In the multivariable diagnosis, lower MAP, higher APACHE II score, higher age, male 
gender, inotrope treatment [OR 2.36 (1.01-5.52)], and a modest increase in SV were 
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independently associated with 90-day mortality. After adjustment with propensity to 
receive inotropes, the results were unchanged, except for inotrope treatment, which was 
no longer significant. We also found that in inotrope receivers the ability to increase SV in 
response to inotrope treatment was associated with survival at 90 days (p=0.003). 
 
	  Figure	  9.	  Kaplan	  Meier	  survival	  plot	  of	  inotrope	  receivers	  and	  non-­‐receivers	  in	  Study	  I.	  	  	  	  
6.2 EARLY HEMODYNAMIC VARIABLES AND OUTCOME IN 
SEVERE ACUTE PANCREATITIS (II) 
 
Of the 159 patients with SAP in Study II, the majority (64.2%) received vasopressors 
during the first 24 hours. In 73 patients, the norepinephrine dose exceeded 0.1 µg/kg/min 
for at least one hour.  These patients constituted the subgroup of patients with circulatory 
shock. Inotropes were administered to 26 patients (16.4%); nearly all of these patients 
(25/26) received dobutamine. A minority of the patients (15.1%) also received 
hydrocortisone for hemodynamic support. A total of 38 patients (23.9%) underwent 
abdominal surgery during their ICU stay. In 19 patients (11.9%), primary surgery was 
performed within 24 hours of ICU admission. 
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The 90-day mortality for all patients with SAP was 15.1%. Early mortality (within 14 
days) accounted for half of the deaths. In the subgroup of 73 patients with circulatory 
failure, 90-day mortality was significantly higher, 26.0%. 
 
Age (p=0.001), but not gender or etiology of pancreatitis, was associated with 90-day 
mortality. Time spent in hospital before referral to the ICU had no association with 
outcome. More severe illness, in terms of higher APACHE II and day 1 SOFA scores, was 
also associated with 90-day mortality (p≤0.001). The use of inotropes per se, higher doses 
of norepinephrine, and higher lactate values, all indicating hemodynamic failure within 
the first 24 hours, were also associated with 90-day outcome. Patients who succumbed to 
the disease had lower minimum values of MAP [66.1 (61.0 -70.6) vs. 71.1 (64.3-80.0) 
mmHg, p=0.002]. Indicators of impairment of renal function, such as lower hourly urine 
output, higher SCr values, and higher renal SOFA subscore were also associated with 
death at 90 days (p<0.002 for all). Patients who underwent surgery at any time during 
their ICU stay had significantly higher 90-day mortality than those who did not (26.3% 
vs. 11.6%, p=0.006). 	  
For the whole study group, advanced age, higher serum creatinine, and lower MAP 
were independently associated with 90-day mortality. In the subgroup of patients with 
circulatory shock, higher APACHE II score, lower CI, and higher CVP predicted 90-day 
mortality. 
 
 
 6.3	  PREDICTION	  OF	  FLUID	  RESPONSIVENESS	  BY	  CHANGES	  IN	  HEMODYNAMIC	  VARIABLES	  DURING	  ELEVATION	  OF	  PEEP	  IN	  SEPTIC	  SHOCK	  (III)	  	  	  
Of the 20 patients studied, 30% were fluid responders, as defined by an increase in CO by 
at least 15% subsequent to a fluid challenge. In fluid responders, DO2 increased as a result 
of the fluid challenge, while in non-responders it decreased. 	  
The best predictors of fluid responsiveness were PEEP-induced decreases in MAP and 
systolic arterial pressure (∆MAP and ∆SAP). We found no association of changes in 
echocardiographic measurements, LVEDA, and VTIAo induced by elevated PEEP (from 10 
to 20 cm H2O) with fluid responsiveness. The catheter-derived filling pressures CVP or 
PAOP were not able to predict fluid responsiveness either at baseline or during elevation 
of PEEP. The differences in decrease in CO or VTIAo were not statistically significant 
between responders and non-responders. 
 
In the ROC analysis, the AUC for the change in MAP (∆MAP) and the change in 
systolic arterial pressure (∆SAP) induced by elevated PEEP (CI 95%) were 0.91 (0.77-1.0) 
and 0.82 (0.64-1.0), respectively. 
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Figure 10. Change in MAP during elevation of PEEP from 10 to 20 cm H2O in fluid non-
responders and fluid responders. Reference line is set at ∆ MAP -8%. 
 
 
By the Youden Index, the best cut-off for ∆MAP was -10.2, sensitivity 83% (95% CI 
0.44-0.97), but the best cut-off for clinical purposes was a decrease in MAP by at least 8%, 
with a sensitivity and an NPV of 100%.  
 
 
 	  
6.4 ASSOCIATION BETWEEN EARLY HEMODYNAMICS AND 
PROGRESSION OF AKI IN SEVERE SEPSIS (IV) 
 
Of the 423 patients with severe sepsis, 153 (36.2%) developed AKI during the first five 
days in the ICU. In 51 patients (12.1%), AKI progressed further during days 1 to 5, and 34 
patients (8.0%) received RRT.  The patients who developed AKI more often suffered from 
septic shock (87.6% vs. 68.5%, p<0.001). Patients who developed AKI more often had 
diabetes (type I or II) and chronic kidney disease (CKD), but not hypertension, as 
comorbidities prior to ICU admission.  A greater portion of patients who developed AKI 
had also been subject to radiocontrast dye and colloids preceding ICU admission.  	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Figure 11. AUCs of ∆MAP and ∆SAP in ROC analysis of Study III. 
 	  
Generally, patients who developed AKI appeared more severely hemodynamically 
compromised in terms of requirements for vasopressor and inotrope support, in addition 
to lower blood pressure levels, during the first 24 hours in ICU. The time-adjusted MAP 
was significantly lower in patients who developed AKI than in those who did not [74.4 
(68.3-80.8) vs. 78.6 (72.9-85.4) mmHg]. Patients developing AKI also spent significantly 
longer periods of time at values of MAP lower than 70 mmHg (55-70 mmHg) (p<0.05). 
These patients received norepinephrine more often and at higher doses, both during the 
first 24 hours and throughout the study period (p<0.001 for all). A substantially greater 
portion of patients with AKI also received inotrope treatment (26.1% vs. 7.1%, p<0.001). 
 
In the ROC analysis, by use of the Youden Method, the best cut-off for time-adjusted 
MAP for the first 24 hours was 72.7 mmHg for prediction of progression of AKI. As for 
dose of norepinephrine, the best cut-off was 0.19 µg/kg/min.  
 
In the multivariable regression analysis, highest lactate during 24 hours, CKD, daily 
dose of intravenous furosemide, and time-adjusted MAP per mmHg [odds ratio (OR) 
0.96; 95% CI 0.94 to 0.99] were independent predictors of progression of AKI. In the 
second model to which time-adjusted MAP of 73 mmHg was added as a categorical 
variable, highest lactate, CKD, daily dose of intravenous furosemide, dobutamine 
treatment, and time-adjusted MAP below 73 mmHg were independent predictors of 
progression of AKI. 
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Figure 12. Incidence of AKI by quartiles of time-adjusted MAP during the first 24 hours in 
the ICU (Study IV). 
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6.5 VASOACTIVE TREATMENT OF CRITICALLY ILL PATIENTS 
WITH SEPSIS AND SEVERE ACUTE PANCREATITIS (I, II, and 
IV) 	  
In the two retrospective studies of septic shock and SAP, the maximum doses of 
norepinephrine infusions were 0.31 (0.14-0.69) and 0.07 (0.0-0.23) µg/kg/min, 
respectively. In the study of patients with septic shock, norepinephrine treatment was a 
prerequisite for inclusion in the study. Inotropes were received by 44.3% of patients with 
septic shock and by 16.4% of patients with SAP.  In these two studies, patients who 
received inotropes received significantly higher doses of vasopressors [0.56 µg/kg/min 
(0.25 – 1.14) vs. 0.20 µg/kg/min (0.10-0.39) for patients with septic shock, and 0.32 
µg/kg/min (0.13-0.55) vs. 0.029 (0.0-0.18) for patients with SAP]. In both studies, the 
maximum dose of norepinephrine administered during the first 24 hours and the use of 
inotropes per se were associated with 90-day mortality. In patients with SAP, the highest 
norepinephrine dose and the use of inotrope treatment were also associated with early 
death (≤ 14 days). 
In the prospective study of patients with severe sepsis, the maximum dose of 
norepinephrine was 0.19 µg/kg/min (0.07-0.47) for patients who developed AKI and 
0.08 µg/kg/min (0.00-0.19) for those who did not. In this study, the dose of 
norepinephrine was associated not only with progression of AKI (p<0.001) but also with 
90-day mortality (p=0.037), despite the fact that all patients who died within the first five 
days were excluded from the study. The use of inotropic substances was associated with 
development of AKI, but not with 90-day mortality.  
 
Vasopressin was used in only one patient in the SAP study. In patients with septic 
shock, it was administered to 16 patients (3.8%). Both the use of  (p=0.001) and the dose 
of vasopressin (p=0.012) were associated with 90-day mortality in this group of patients. 
In patients with severe sepsis, vasopressin was used in only 5 patients, 4 of whom 
developed AKI. The difference did not reach statistical significance (p=0.06) regarding 
AKI or 90-day mortality (p=1.0). 
 
In patients with septic shock, sepsis corticosteroid treatment was initiated in 60.2% as 
hemodynamic support. Sepsis corticosteroids were administered to 15.1% of patients with 
SAP. In both studies, hydrocortisone treatment was significantly associated with 90-day 
mortality (p<0.001). In the prospective study of patients with severe sepsis, 23.9% 
received sepsis corticosteroids.  In the subgroup of patients who received norepinephrine 
during the first 24 hours, the proportion was 31.5%. Consistent with the two retrospective 
studies, corticosteroid treatment was associated with both progression of AKI (p<0.001) 
and death at 90 days (p=0.01) also in this prospective study. 
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6.6 OUTCOME OF SEVERE SEPSIS, SEPTIC SHOCK, AND 
SEVERE ACUTE PANCREATITIS (I, II, and IV) 
 	  
In Study I, the mortality in the two ICUs for patients with septic shock was 17.4%, the 
hospital  mortality was 24.5%, and the 90-day mortality was 32.1%. In patients with 
severe acute pancreatitis, the mortality rates were substantially lower: the ICU mortality 
was 8.8%, the hospital mortality 13.2%, and the 90-day mortality 15.1%.  
When the 70 excluded patients in the severe sepsis group who had died within days 1 to 5 
were included in the mortality rates, the ICU mortality in 13 Finnish ICUs was 18.5% and 
the 90-day mortality 34.7%. 	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7. DISCUSSION 	  
STRENGTHS AND WEAKNESSES OF THE STUDY 
 
In Studies I and II, the study populations were large and a considerable portion of the 
patients were monitored by a PAC, providing detailed hemodynamic data of patients with 
septic shock. Despite being retrospective studies, the hemodynamic data and data on 
vasoactive treatment were prospectively registered into the clinical patient data system, 
improving the quality of these data. The adjustment with propensity to receive inotropes 
also reduced some bias in this retrospective study. The incorporation of TEE and PAC-
derived variables into Study III contributed to a large set of assessed hemodynamic 
variables, allowing a more focused approach in future studies. The large and prospective 
multicenter data of Study IV, in addition to the highly detailed MAP data, add strength to 
this study. Moreover, a large set of data of factors associated with development of AKI 
was prospectively collected, also providing strength to the study. Lastly, 90-day mortality 
was used as an outcome measure; this is more informative than 28-day or 30-day 
mortalities, which have mostly been used previously. Critically ill patients often require 
ICU and hospital care for long periods of time, sometimes with additional weeks of 
rehabilitation in primary care facilities. 
 	  
There are some limitations to the study. First and foremost, the retrospective design of 
Studies I and II must be noted. Due to their retrospective design, the results of these 
studies may only generate hypotheses and serve as a platform for future prospective 
studies. These studies were also conducted in a single hospital, which may decrease the 
general applicability of the results. Inclusion in these studies was based on diagnoses 
registered in the database, which may have led to erroneous inclusions. The high number 
of patients monitored by PAC may also be considered a limitation, as it does not reflect 
current European ICU practices. Important clinical data, demographic data, and 
laboratory data as well as data on comorbidities were not retrieved in these studies. The 
addition of these variables to the propensity score adjustment in Study I would have 
increased the strength of the model. The lack of data of IAP in Study II also needs to be 
emphasized due to its impact on abdominal perfusion pressure data.  
 
The limited sample size of Study III calls for validation in a larger study population. 
The study was conducted in sedated and mechanically ventilated patients with septic 
shock, with sinus rhythm and no serious comorbidities. Therefore, the results may not 
apply to other groups of patients. Moreover, the changes in hemodynamic variables 
observed in this study may not be observed using other baseline values and increments of 
PEEP. Lastly, the study was not designed for elucidation of the underlying mechanisms of 
hemodynamic changes during elevation of PEEP. 
 
Although prospective, the design of Study IV was observational without 
randomization regarding hemodynamic support. Possibly, therefore, the hemodynamic 
changes observed between patients who did and did not develop AKI were caused by 
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differences in severity of illness. The decision to exclude patients who died during the five 
days of the study in an attempt to decrease the impact of competing risks may be 
considered flawed, as it may have caused selection bias through exclusion of the most 
severely ill patients. Information on abdominal perfusion pressure could not be assessed 
in the study. Information of IAP was registered only in patients in whom elevated IAP was 
suspected, and inclusion of the registered values would thus have led to an increase in 
bias. The relationship between cardiac output and AKI could not be assessed due to lack 
of data on cardiac output. Lastly, although the results indicated an association of use of 
colloids with progression of AKI, we could not deduce the type of colloid used in the ICU, 
which would have been of further interest. 	  	  
 
METHODOLOGICAL CONSIDERATIONS 
 
Due to the retrospective nature of Studies I and II and the observational nature of Study 
IV, any conclusions about causality cannot be drawn. In addition, some other 
methodological factors must be considered. The retrospective identification of patients 
with septic shock and severe acute pancreatitis based on APACHE III and ICD-10 
diagnoses (and need for vasopressor support during the first 24 hours) may have affected 
the composition of the final study population. It may have led to incorrect inclusions and 
exclusions, rendering the study population different or even incomparable to populations 
with septic shock of other studies. On the other hand, retrospective inclusion may lead to 
a more varied admixture of patients through inclusion of patients with varying 
comorbidities, who possibly would have been excluded from a prospective study. One 
might argue that a retrospective study at its best provides a more realistic study 
population that is closer to clinical practice.  By adjusting for propensity to receive 
inotropes, the selection bias was likely diminished. However, propensity scores can only 
adjust for measured variables, and we recognize that many potentially important 
variables affecting initiation of inotrope treatment or outcome were not included in the 
model.  
Data were collected over a four-year period, during which changes in the treatment of 
critically ill patients may have occurred, potentially affecting the results. In addition, 
some provider-dependent differences in the care of patients may persist despite the 
different ICUs being included in the propensity score to reduce any bias.  
 
While Study III was being performed, many advances were made in assessment of 
fluid responsiveness and bedside echocardiography. At the time of planning the study, 
TEE was widely preferred to TTE in ICU patients. Had the study commenced today, 
transthoracic parameters would probably have been chosen, mainly due to their lack of 
invasiveness and fewer contraindications for use. Numerous methods and appliances for 
assessing fluid responsiveness and CO based on pulse pressure or stroke volume variation 
have been validated in recent years and are now widely used in the ICU. For less invasive 
monitoring, some of these methods could also have been used for assessing the response 
to fluid. However, at the time of the study, the PAC was considered the gold standard for 
CO assessment.  
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The prospective design of Study IV was appropriate for assessing the association 
between hemodynamic factors and progression of AKI. However, the inclusion of patients 
over a six-month period was performed during the autumn and winter months, which 
may have had an impact on the occurrence of severe sepsis due to seasonal variation. The 
geographical coverage of the 17 ICUs was good. The choice of patients with severe sepsis 
for the analysis could have been supplemented by a substudy of patients with septic 
shock, as these patients seem to be at greatest risk of developing AKI. Furthermore, as 
evidenced by earlier studies, 126 hemodynamic variables and vasoactive treatment seem to 
matter most in this group of patients, in which derangements of autoregulation of end-
organ blood flow plausibly are most severe. As for the multivariable regression analyses of 
Studies I, II, and IV, the choice of variables in the models may be debated. We aimed at 
including variables lacking interrelationships, but as several hemodynamic variables and 
a given treatment may be correlated, the variables chosen may not always be fully 
independent.  
 	  
 
ASSOCIATION OF INOTROPE TREATMENT WITH OUTCOME IN 
SEPTIC SHOCK 
 
This study showed that higher CVP, higher doses of norepinephrine, and higher lactate 
values during the first 24 hours in the ICU were associated with inotrope treatment. 
Moreover, inotrope treatment, higher APACHE II score, and higher age were 
independently associated with 90-day mortality. Dobutamine was used in 90% of 
inotrope receivers.  
 
This is one of the first studies assessing the association of inotrope treatment with 
outcome in patients with septic shock. Current guidelines recommend the use of 
dobutamine for raising CO and tissue perfusion in patients with septic shock when the 
response to fluid and vasopressors is inadequate. 35 The evidence supporting the use of 
dobutamine is nevertheless rather weak.  Evidence exists that dobutamine may increase 
CO and venous oxygen saturation and may possibly be advantageous for splanchnic 
circulation.  336,337 However, a recent study failed to show any benefit of dobutamine 
treatment in terms of tissue perfusion, despite an increase in CO.  336 
 
 In a recent large retrospective study, the use of inotropes was associated with higher 
mortality and development of AKI, even after adjustment for propensity to receive 
inotropes.  338 Dobutamine, milrinone, and epinephrine were defined as inotropes; 
levosimendan was not used in their patient group. In patients with heart failure, 
dobutamine may be associated with worse outcome, also in terms of mortality, when 
compared with control treatment or placebo.  310 Levosimendan seems to reduce mortality 
in cardiac surgery and cardiology settings. Insufficient data exist of its use in patients with 
septic shock.  313 
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The adverse effects of catecholamine inotropes, such as arrhythmias, increased 
myocardial oxygen consumption, and elevated risk of myocardial ischemia, are fairly well 
known. Furthermore, and perhaps more interestingly, dobutamine has been shown to 
affect innate immunity in a pro-inflammatory manner, as opposed to norepinephrine.  
34Evidence also exists that catecholamines, in addition to being enhancers of biofilm 
formation, may be potent stimulators of bacterial growth by participating in bacterial iron 
metabolism.  339,340 
 
In the current study, higher lactate values, higher norepinephrine values, and higher 
CVP were associated with inotrope treatment. This finding is not surprising since all of 
these parameters may reflect a more severe hemodynamic compromise. A higher CVP 
value may partly reflect futile attempts to stabilize the patient by vigorous fluid 
resuscitation, but it may also be explained by an inability to adapt to the increase in 
volume, in other words, being the price paid for volume expansion. 161,250 Higher doses of 
norepinephrine in this study were probably required in more severely ill patients with 
more profound vascular hyporesponsiveness.  341 
Higher lactate values are most probably explained by impaired tissue perfusion and 
anaerobic metabolism, thus serving as an indication for initiation of inotropes. 342,343 
However, a decision to initiate inotrope treatment is not always based on correct 
indications. High lactate levels might not be caused by insufficient CO, but instead by 
aerobic glycolysis and mitochondrial disturbances, and therefore, should not be corrected 
by inotropes.  344-346 
Inability to respond to dobutamine by an increase in SV has earlier been shown to be 
associated with poor outcome in septic shock. 347 This finding was also confirmed in our 
study. In patients receiving inotropes, the ability to increase SV was associated with better 
outcome. In patients not receiving inotropes, the change in SV had no bearing on 
outcome. This phenomenon may be explained by a cardiovascular or preload reserve in 
inotrope responders, which is associated with a more favorable outcome.  29,348 Lately, 
diastolic dysfunction has been found to be associated with poor outcome in septic shock.  
163,164,349 Catecholamine inotropes may not be the ideal treatment for these patients, as 
they may induce increased myocardial stiffness.  350-352 
 
Although inotropes may be beneficial in short-term use for patients with septic shock, 
the beneficial effects may be outweighed by deleterious ones over time, ultimately leading 
to worse long-term outcomes. Moreover, some patients, particularly those who do not 
respond favorably to dobutamine by elevation of SV, possibly will not benefit from the 
treatment, but are merely exposed to different adverse effects. Based on the retrospective 
design of this study, no definite conclusions can be drawn. However, evidence from this 
and other studies suggest that the use of inotropes may indeed be associated with worse 
outcome in patients with septic shock. Therefore, randomized prospective studies to 
scrutinize the causality of this observed association are justified. 
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ASSOCIATION OF EARLY HEMODYNAMIC VARIABLES WITH 
OUTCOME IN SEVERE ACUTE PANCREATITIS  
 
Few studies have assessed the association between hemodynamics and outcome in SAP.  
353Although fluid treatment is advocated in all current guidelines for severe pancreatitis, 
there is great uncertainty regarding hemodynamic targets for resuscitation and details of 
fluid resuscitation to optimize outcome are scant. 19,354 Although SAP has several 
similarities with septic shock 355, current guidelines for management of septic shock may 
not be optimal for management of SAP.    
 
Advanced age, higher serum creatinine, and lower MAP were independent risk factors 
for 90-day mortality in patients with SAP in this study. In the subgroup of patients with 
circulatory shock, higher APACHE II score, higher CVP, and lower CI were independently 
associated with 90-day mortality.  
 
Previously, results from a small retrospective study by Malcynski and coworkers 
showed that high blood lactate values, low arterial blood pressure, and high heart rate 
were associated with adverse outcome in this group of patients, all being indicators of a 
more profound circulatory failure, as was the use of vasopressors and inotropes.  353 In the 
present study, these findings were confirmed, except for heart rate, which had no 
association with outcome.  
 
The theoretical basis for aggressive fluid resuscitation is that rapid restoration of the 
microcirculation will prevent further local damage and prevent escalation of the disease 
and ultimately the development of organ failure. 356 Early mortality in SAP has been 
attributed mainly to cardiopulmonary failure and early multi-organ dysfunction. Late 
mortality is predominantly caused by infectious complications and consequent organ 
dysfunction. Although infectious complication may lead to organ failure, there is also 
some evidence of an opposite causal relationship. Multiple organ dysfunction (MOD) has 
been shown to precede infectious complications by an average of two weeks. MOD is thus 
thought to cause deterioration of the immune response, facilitating bacterial translocation 
and development of uncontrolled infection. 357 Be that as it may, early hemodynamics and 
resuscitation have considerable importance for both early and late outcome measures. 
 
Nonetheless, overzealous rehydration does not appear to be the solution to the 
problem of how to optimally manage hemodynamics. As in other groups of critically ill 
patients,  200,358 there is now some evidence that excessive fluid load is associated with 
worse outcome in patients with SAP. 359 We found that in patients with SAP and 
circulatory shock, a higher CVP and a lower CI were associated with 90-day mortality. 
Higher CVP has also been associated with poor outcome in patients with septic shock  200 
and in patients with SAP. 360 Due to the design of our study, the underlying cause for this 
association could not be determined. We can only hypothesize that it may be due to either 
excess fluid resuscitation or impaired myocardial function with a concomitant inability to 
adjust and benefit from the volume expansion,  161,250 or plausibly both. The hypothesis of 
impaired cardiac contractility is supported by the fact that low CI also was associated with 
poor outcome. 
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Over the last decades, concerning many patient groups in the ICU, the pendulum has 
swung from restrictive fluid administration to liberal fluids, and back again. Some of this 
change may be the result of temporal fluctuations in current perceptions of what is right 
according to the rule of art. Nevertheless, acknowledging that fluids are drugs with an 
optimal dosage and potential side-effects makes sense, especially in the face of recent data 
pointing to important adverse effects.  256,257 
In addition to optimal fluid resuscitation, information regarding appropriate targets 
for hemodynamic management is urgently needed. The current study showed that low 
blood pressure is associated with worse outcome, but this may be explained by both more 
severe disease and suboptimal management. Furthermore, as this study could not analyze 
the association of IAP or abdominal perfusion pressure with outcome, an important piece 
in the hemodynamic puzzle is regrettably missing. As shown by two recent meta-analyses 
of hemodynamic treatment and fluid resuscitation of patients with SAP, large prospective 
randomized studies for assessing optimal hemodynamic management of early SAP are 
clearly warranted.  19,20 
 
 
	  
PREDICTION OF FLUID RESPONSIVENESS BY ELEVATION OF PEEP IN 
PATIENTS WITH SEPTIC SHOCK 
 
In the current study, a decrease in SAP and MAP during elevation of PEEP from 10 to 20 
cm H2O predicted fluid responsiveness in mechanically ventilated patients with septic 
shock. In the ROC analyses, the AUC for the changes in MAP and SAP was 0.91 and 0.82, 
respectively. These predictive values are comparable with those of PPV and SVV.   38 For 
clinical use, the most important result was that MAP decreased by 8% or more during 
elevation of PEEP in all patients who responded favorably to fluid challenge. The results 
indicate that the current method could be used for ruling out fluid responsiveness in this 
group of patients, using only the ventilator and an arterial pressure line.  	  
During the time period that this study was conducted many dynamic means of 
assessing fluid responsiveness were assessed and validated.  38,361 Nonetheless, the issue of 
predicting fluid response continues to puzzle clinicians. The translation of methods 
proven reliable in experimental or clinical studies into everyday practice is not always 
easy and straightforward. Accurate methods may not even be reliable when transferred 
from bench to bedside, a problem that has been stressed in recent studies 362,363 Moreover, 
only a few echocardiographic methods have been validated against the gold standard, 
namely CO assessment by thermodilution. 238 Due to individual ventilator settings based 
on differences in pulmonary function and consciousness, arrhythmias, and occasional 
contra-indications to the use of particular means of assessing fluid responsiveness, one 
method of assessing fluid responsiveness will not fit all patients at all times.  
The most important and challenging part of predicting fluid responsiveness is the 
determination of which patients will not benefit at all from further fluid, as given fluid 
cannot be easily removed. In the current study, the calculated oxygen supply decreased in 
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non-responders subsequent to the volume expansion, while it increased in responders, 
further emphasizing the importance of knowing when to give fluid and when to stop. 
 
Somewhat surprisingly, neither LVEDA nor VTIAo at baselineor during PEEP were 
associated with a positive response to fluid in this study. Earlier results regarding the 
predictive value of LVEDA for assessment of fluid responsiveness in critically ill patients 
have been controversial. 364 As for VTIAo, we may only hypothesize that squeezing of 
pulmonary beds may counteract the decrease in venous return induced by PEEP or that 
changes in the dimensions of the aortic root may attenuate the change in VTIAo. The 
decrease in CO during elevation of PEEP measured by thermodilution was not predictive 
of fluid responsiveness. CO decreased significantly in all patients during PEEP, without 
significant differences between the groups.  
The study group being rather small and the patients being mechanically ventilated and 
sedated prevent direct application of these findings to other study groups. In addition, the 
results need validation in a larger population. 
 
 
 
EARLY HEMODYNAMIC VARIABLES AND DEVELOPMENT OF ACUTE 
KIDNEY INJURY IN SEVERE SEPSIS 
 
This study demonstrated that time-adjusted MAP during the first 24 hours in ICU was 
independently associated with the progression of AKI. Other factors associated with 
progression of AKI were higher lactate levels, CKD, dose of intravenous furosemide, and 
use of dobutamine. Patients who developed AKI had significantly lower time-adjusted 
MAP over the first 24 hours and they also spent a significantly longer period of aggregate 
time below MAP threshold levels of 75 mmHg.  The best cut-off level of MAP for 
prediction of development of AKI was 73 mmHg. These results suggest that maintaining 
MAP over 73 mmHg and minimizing time spent at MAP below 75 mmHg would protect 
the kidney and prevent progression of AKI.  
 
There is some evidence also from earlier studies that MAP higher than the currently 
recommended level of ≥ 65 mmHg is needed for protecting kidney function of patients 
with severe sepsis. In the prospective study by Badin and coworkers, a level of over 72 
mmHg seemed to protect patients with septic shock from progressing to AKI. In patients 
with shock for other reasons, no association between MAP and AKI was found.  126 Similar 
results were demonstrated by Dünser and coworkers in a retrospective study. Hourly 
blood pressure time integrals were associated with initiation of RRT, serum creatinine, 
and urine output, but not with parameters describing liver function.  43 
 
The finding that higher blood pressure levels may protect the kidney appears 
reasonable in light of previous evidence. Data from two recent studies of limited size 
demonstrated that in shock patients an increase in MAP from 65 to 75 mmHg leads to 
improvements in glomerular filtration and urine output.  44,365 Several earlier studies have 
shown similar results.  282,366,367  
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Nonetheless, two recent rather small prospective studies failed to show any benefit in 
renal function with an increase in MAP. However, in the work by Bourgoin and 
coworkers, MAP was raised from 65 mmHg to 85 mmHg in the intervention group. This 
level might be too high for beneficial effects, as proposed by Badin and coworkers. 126 
Furthermore, evidence exists that any increment in MAP over 70 mmHg in patients with 
septic shock via an increase in vasopressor load 45 is associated with worse outcome. In 
the study by LeDoux and coworkers, MAP was elevated by use of norepinephrine to 75 
mmHg and subsequently to 85 mmHg. In this study, there was an increase in urine 
output when increasing MAP from 65 mmHg to 75 mmHg, but a decrease to below 
baseline value when MAP was further elevated via norepinephrine to 85 mmHg. There 
was also a trend of higher lactate values when targeting MAP values over 85 mmHg, in 
addition to a less favorable SVO2. To achieve the MAP target of 85 mmHg, a more than 
two-fold dose of norepinephrine was needed relative to the requirements at a baseline 
MAP of 65 mmHg. 368 The results of these two studies are therefore not comparable with 
the more recent studies targeting a MAP of 75 mmHg.  
 
The current study also demonstrated that higher doses of norepinephrine were 
associated with, but were not an independent predictor for, progression of AKI. This 
finding is plausibly explained by an increase in adverse affects of catecholamines with 
increasing doses. 45 It is possible that excessive use of norepinephrine causes harmful 
vasoconstriction of regional vascular beds, resulting in deterioration in renal perfusion 
and renal function. 369 The relationship between vasopressor requirements and 
progression of AKI may also be explained by patients with more severe disease requiring 
higher vasopressor doses, which consequently leads to higher incidences of end-organ 
failure.  85 
 
The study also showed that a higher fluid load and use of colloids were associated with 
progression of AKI and worse outcome. Earlier data imply that fluid load is associated 
with impaired renal recovery and generally worse outcomes in critically ill patients. 268 
The adverse effects of hydroxyethyl starches on renal function and outcome have also 
been highlighted in recent studies.  256,257 
 
The clinical problem is how to balance between excessively high and low levels of MAP 
to protect the kidney. There is also the consideration of optimal dosage of norepinephrine 
for best possible outcome. Lastly, one cannot overlook the importance of optimal fluid 
resuscitation for kidney function as well as for optimizing outcome. The balance between 
too little and too much is further complicated by differences in disease severity and 
comorbidities of critically ill patients.  	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OUTCOME IN SEVERE SEPSIS, SEPTIC SHOCK, AND SEVERE ACUTE 
PANCREATITIS 
 
In this study, the mortality of severe sepsis and septic shock was consistent with that of 
the earlier Finnish multicenter FINNSEPSIS study  10 and also with international studies.7 
The mortality of patients with SAP was comparable with or slightly lower than in previous 
studies.  22-24 Interestingly, early deaths accounted for half of the deaths, as has been noted 
elsewhere. 24 Although information on the incidence of AKI in severe sepsis using the new 
KDIGO criteria is lacking, the incidence of AKI in this study is largely consistent with data 
from earlier studies. 370 The incidence of AKI in severe sepsis was slightly lower than in 
the previously presented FINNAKI study, plausibly due to differences in the inclusion 
criteria, excluding patients who died during days 1-5 in the ICU and those with onset of 
AKI later than 5 days. 369 
 	  
CLINICAL IMPLICATIONS AND FUTURE PERSPECTIVES 
 
The results of this study may serve as a platform for further randomized controlled trials 
aimed at determining the impact of inotrope use in critically ill patients, the 
hemodynamic targets for fluid resuscitation in SAP, the predictive value of a decrease in 
blood pressure during elevation of PEEP, and the impact of higher MAP on the 
progression of AKI. While anticipating the results of such studies, these findings provide 
food for thought for clinicians concerning everyday ICU practice. While only hypothesis 
generating, our results indicate that inotrope treatment in patients with septic shock may 
be associated with adverse outcome, and the benefits and harms of such treatment should 
always be carefully considered. In addition, our results suggest that no or only a modest 
decrease in MAP during elevation of PEEP in patients with septic shock is indicative of 
lack of positive fluid response to a fluid challenge. This straightforward and swift method 
may help clinicians to avoid harmful overhydration. Furthermore, our results imply that 
maintaining MAP over 75 mmHg in patients with severe sepsis may prevent onset and 
progression of AKI.  
 
In many fields, such as in the hemodynamic support of patients with SAP, there is a 
paucity of elementary information on optimal management and targets for resuscitation. 
In such fields, large randomized studies are urgently needed. This also applies to the 
hemodynamic management of patients with severe sepsis or septic shock. To prevent the 
development or progression of AKI, which is responsible for a substantial increase in the 
morbidity and mortality of these patients, a large prospective randomized study is 
justified. Due to the vast number of confounding factors, such a study would have to be 
standardized not only by severity of illness but also by hemodynamic support provided. 
The predictive value of a decrease in MAP for assessing fluid responsiveness also needs to 
be validated in a larger population before definite conclusions can be made of its 
usefulness in clinical practice. Furthermore, based on our results and those of a recent 
crossover study evaluating the effects of dobutamine infusion, there is reason to doubt 
that inotropes are exclusively beneficial for patients with septic shock. The impact of 
inotropes on outcome should be assessed in a large randomized prospective study.  
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The development of intensive care appears to have reached a crossroads. In many 
aspects, results and outcomes have improved markedly over the last decades. However, 
only marginal further improvements can be achieved by general guidelines for the whole 
population of shock patients or patients with SAP or, for that matter, the entire 
population of critically ill patients.  
 
For instance, inotrope administration may not be universally beneficial for all septic 
patients with low cardiac output. There may, however, be a specific subgroup of patients 
who would benefit, and this group should be identified. Prospective randomized studies 
will eventually shed some light on enigmas such as this, but we also need further 
information of the genomics and individual properties of each patient to be able to 
provide optimal tailored treatment for patients admitted to the ICU.  
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8. CONCLUSIONS 	  	  
Based on the results of this study, the following conclusions can be drawn: 
 
 
1. Inotrope treatment was independently associated with 90-day mortality 
for all patients with septic shock. The results remained unchanged after 
adjustment with propensity score. In the subgroup of patients monitored 
with PAC, failure to increase in SV, but not inotrope use per se, was 
associated with 90-day mortality. 
 
 
2. Advanced age, higher serum creatinine, and lower MAP were 
independently associated with 90-day mortality in patients with SAP. In 
patients with SAP and circulatory shock, higher CVP and lower CI were 
independent predictors for 90-day mortality.  
 
 
3. A decrease in MAP during elevation of PEEP from 10 to 20 cm H2O 
predicted fluid responsiveness in patients with septic shock. A decrease in 
MAP of less than 8% during elevation of PEEP excluded a positive 
response to a subsequent fluid challenge, with a NPV of 100%. 
 
 
4. Time-adjusted MAP was significantly lower and independently associated 
with progression of AKI in patients with severe sepsis. In addition, chronic 
kidney disease, lactate level, dose of intravenous furosemide, and use of 
dobutamine were independent predictors of progression of AKI.  The 
results suggest that avoiding hypotensive episodes below 73 mmHg may 
prevent progression of AKI. 
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